WO2020209266A1 - 花粉形成能の低いステビア植物 - Google Patents
花粉形成能の低いステビア植物 Download PDFInfo
- Publication number
- WO2020209266A1 WO2020209266A1 PCT/JP2020/015729 JP2020015729W WO2020209266A1 WO 2020209266 A1 WO2020209266 A1 WO 2020209266A1 JP 2020015729 W JP2020015729 W JP 2020015729W WO 2020209266 A1 WO2020209266 A1 WO 2020209266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- plant
- base
- allele
- homozygous
- Prior art date
Links
- 241000544066 Stevia Species 0.000 title claims abstract description 133
- 241000196324 Embryophyta Species 0.000 claims abstract description 186
- 235000019202 steviosides Nutrition 0.000 claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 claims abstract description 45
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 44
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 44
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 44
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 44
- 239000000284 extract Substances 0.000 claims abstract description 43
- 230000002068 genetic effect Effects 0.000 claims description 235
- 108700028369 Alleles Proteins 0.000 claims description 171
- 238000000034 method Methods 0.000 claims description 156
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 claims description 46
- 230000035772 mutation Effects 0.000 claims description 41
- 238000012360 testing method Methods 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000012216 screening Methods 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 12
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 11
- 238000002703 mutagenesis Methods 0.000 claims description 9
- 231100000350 mutagenesis Toxicity 0.000 claims description 9
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 claims description 5
- OMHUCGDTACNQEX-OSHKXICASA-N Steviolbioside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OMHUCGDTACNQEX-OSHKXICASA-N 0.000 claims description 5
- JLPRGBMUVNVSKP-AHUXISJXSA-M chembl2368336 Chemical compound [Na+].O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C([O-])=O)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O JLPRGBMUVNVSKP-AHUXISJXSA-M 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 210000001938 protoplast Anatomy 0.000 claims description 4
- 210000002257 embryonic structure Anatomy 0.000 claims description 3
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229930188195 rebaudioside Natural products 0.000 claims description 2
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 claims description 2
- QRGRAFPOLJOGRV-UHFFFAOYSA-N rebaudioside F Natural products CC12CCCC(C)(C1CCC34CC(=C)C(CCC23)(C4)OC5OC(CO)C(O)C(OC6OCC(O)C(O)C6O)C5OC7OC(CO)C(O)C(O)C7O)C(=O)OC8OC(CO)C(O)C(O)C8O QRGRAFPOLJOGRV-UHFFFAOYSA-N 0.000 claims description 2
- GSGVXNMGMKBGQU-PHESRWQRSA-N rebaudioside M Chemical compound C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GSGVXNMGMKBGQU-PHESRWQRSA-N 0.000 claims description 2
- HYLAUKAHEAUVFE-AVBZULRRSA-N rebaudioside f Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HYLAUKAHEAUVFE-AVBZULRRSA-N 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 85
- 239000002773 nucleotide Substances 0.000 description 70
- 125000003729 nucleotide group Chemical group 0.000 description 70
- 108091033319 polynucleotide Proteins 0.000 description 21
- 102000040430 polynucleotide Human genes 0.000 description 21
- 239000002157 polynucleotide Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 238000001962 electrophoresis Methods 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 238000012408 PCR amplification Methods 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000954177 Bangana ariza Species 0.000 description 9
- 238000012795 verification Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000004885 tandem mass spectrometry Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 4
- QSIDJGUAAUSPMG-CULFPKEHSA-N steviolmonoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QSIDJGUAAUSPMG-CULFPKEHSA-N 0.000 description 4
- 238000012225 targeting induced local lesions in genomes Methods 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000011880 melting curve analysis Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000021332 multicellular organism growth Effects 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010061979 CEL I nuclease Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 108010041758 cleavase Proteins 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002015 leaf growth Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8222—Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation
- C12N15/823—Reproductive tissue-specific promoters
- C12N15/8231—Male-specific, e.g. anther, tapetum, pollen
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/02—Methods or apparatus for hybridisation; Artificial pollination ; Fertility
- A01H1/022—Genic fertility modification, e.g. apomixis
- A01H1/023—Male sterility
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/04—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection
- A01H1/045—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection using molecular markers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/10—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits
- A01H1/101—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine or caffeine
- A01H1/102—Processes for modifying non-agronomic quality output traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine or caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
- A01H1/103—Non-starch polysaccharides, e.g. cellulose, fructans or levans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/12—Processes for modifying agronomic input traits, e.g. crop yield
- A01H1/121—Plant growth habits
- A01H1/1215—Flower development or morphology, e.g. flowering promoting factor [FPF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/12—Leaves
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/14—Asteraceae or Compositae, e.g. safflower, sunflower, artichoke or lettuce
- A01H6/1488—Stevia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/36—Terpene glycosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/13—Plant traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a Stevia plant having a low pollen-forming ability, a method for producing the same, a method for screening, and the like.
- Stevia is a perennial plant of the Asteraceae family that originates in Paraguay, South America. Stevia contains various sweetening components having a sweetness of several tens to several hundred times that of sugar, and these sweetening components are extracted and used as a natural sweetener (Patent Document 1). However, there are still many unknowns about the genetic information of Stevia and what kind of genes are involved in the control of in vivo events.
- the present invention provides a Stevia plant having a low pollen-forming ability, a method for producing the plant, a method for screening, and the like.
- the invention provides: [1] Stevia plant with lower pollen forming ability than wild type. [2] Heterozygous for alleles where the base at position 79 of SEQ ID NO: 151 is C, heterozygous for alleles where the base at position 65 of SEQ ID NO: 152 is T The plant according to [1], which is heterozygous or homozygous for an allele in which the base at the position corresponding to position 24 of SEQ ID NO: 153 is T. [3] The plant according to [1] or [2], further having at least one of the following genetic features (1) to (7). (1) It is homozygous for an allele in which the base at the position corresponding to position 40 of SEQ ID NO: 2 is T.
- [4] The plant according to [3], which has at least one of the following characteristics (1) and (2).
- (1) Contains 3% or more RebD per unit mass of dried leaves.
- (2) Contains 0.2% or more of RebM per unit mass of dried leaves.
- [5] The plant according to any one of [1] to [4], which is a non-genetically modified plant.
- [6] The plant according to any one of [1] to [5], which comprises a Stevia plant which has undergone mutagenesis treatment and a progeny plant thereof.
- [7] The seed, tissue, tissue culture or cell of the plant according to any one of [1] to [6].
- tissue, tissue culture or cell according to [7] selected from embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections and callus.
- a method for producing a Stevia plant having a low pollen-forming ability which comprises a step of crossing the plant according to any one of [1] to [6] with a second Stevia plant.
- Stevia extract comprising the step of obtaining an extract from the plant according to any one of [1] to [6], and the seed, tissue, tissue culture or cell according to [7] or [8].
- Production method [13] A step of obtaining an extract from the plant according to any one of [1] to [6], and the seed, tissue, tissue culture or cell according to [7] or [8], and the obtained extract.
- a method for producing a refined steviol glycoside product which comprises a step of purifying a steviol glycoside from the body.
- Steviol glycosides include rebaugioside A, rebaugioside B, rebaugioside C, rebaugioside D, rebaudioside E, rebaudioside F, rebaudioside M, rebaudioside N, rebaugioside O, stevioside, steviolbioside, rubusoside, zulucoside A or a combination thereof.
- Food and drink, sweetness composition including the step of providing the extract or the refined product thereof according to [11] and the step of adding the extract or the refined product to the raw material of the food or drink, the sweetness composition, the flavor or the pharmaceutical. Manufacturing method of goods, fragrances or pharmaceuticals.
- Heterozygous or homozygous for alleles whose base at position 79 of SEQ ID NO: 151 is C, heterozygous or homozygous for alleles whose base at position 65 of SEQ ID NO: 152 is T Includes reagents for detecting the presence and / or absence of the genetic feature of being heterozygous or homozygous for an allele in which the base at position 24 of SEQ ID NO: 153 is T. , Low pollenogenic ability Stevia plant screening kit. [21] The kit according to [20], further comprising a reagent for detecting the presence and / or absence of the following genetic features (1) to (7).
- a Stevia plant having a low pollen-forming ability acquisition of a Stevia plant having a low pollen-forming ability, a means for producing such a plant, leaves obtained from such a plant, foods and beverages containing an extract obtained from the leaves. Etc. can be provided.
- the pollen-forming ability is low, nutrients that should be originally used for pollen formation are used for leaf growth, which can be expected to improve leaf productivity and eventually increase the content of steviol glycosides accumulated in the leaves.
- FIG. 1 is a diagram showing a frequency distribution of sweetness component content in M1 generation individuals.
- the vertical axis shows the number of individuals, and the horizontal axis shows the sweetness component concentration (%) in the dried leaves.
- FIG. 2 is a diagram showing the distribution of the sweetness component content in the mutant C49A positive individual (C49A + ) and the negative individual (C49A ⁇ ) of the isolated population A.
- the vertical axis shows the sweetness component concentration (%) in the dried leaves, and the dotted line shows the average value of the sweetness component concentration of all the individuals belonging to the isolated group A.
- FIG. 3 is a diagram showing the distribution of the sweetness component content in the mutant C49A positive individual (C49A + ) and the negative individual (C49A ⁇ ) of the isolated population B.
- the vertical axis shows the sweetness component concentration (%) in the dried leaves, and the dotted line shows the average value of the sweetness component concentration of all the individuals belonging to the isolated group B.
- the present invention is a Stevia plant with low pollen-forming ability as compared with the wild type (hereinafter, may be collectively referred to as "plant of the present invention” or "stevia plant of the present invention”). I will provide a. Stevia is a plant with the scientific name of Stevia Rebaudiana Bertoni.
- “Lower pollen-forming ability than wild-type” means, for example, that the number of pollen produced is smaller than that of wild-type Stevia plants when cultivated under the same cultivation conditions. More specifically, for example, when cultivated under the same cultivation conditions, the number of pollen contained in a fully bloomed flower is 20% or more, 25% or more, 30% or more, 35% or more, as compared with the wild-type Stevia plant.
- the pollen contained in a fully bloomed flower is 50 or less, for example, 45 or less, 40 or less, 35 or less, 30 or less. , 25 or less, 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 It may be used that the number is 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 or less.
- "fully bloomed” means a state in which the stigma is extended to the extent that at least one stigma can be visually recognized when the flower is viewed from the side.
- the stevia plant of the present invention is genetically characterized by being homozygous or heterozygous for an allele in which the base at position 79 of SEQ ID NO: 151 is C (hereinafter, “the present invention”.
- the present invention a genetic feature that is homozygous or heterozygous for an allele in which the base at the position corresponding to position 65 of SEQ ID NO: 152 is T (hereinafter, “this” (Sometimes referred to as “genetic feature X-2" of the invention) and the genetic feature that the allele in which the base at the position corresponding to the 24th position of SEQ ID NO: 153 is T is homozygous or heterozygous (hereinafter referred to as heterozygous).
- it has at least one genetic feature (hereinafter sometimes referred to as "genetic feature X of the present invention") of "genetic feature X-3 of the present invention”).
- the stevia plant of the present invention is homozygous for an allele in which the base at the position corresponding to position 201 of SEQ ID NO: 1 is A (hereinafter, "genetic feature A of the present invention”). May be referred to as).
- the Stevia plant of the present invention may be referred to as at least one of the following genetic features (B-1) to (B-4) (hereinafter, “genetic feature B of the present invention”). ).
- B-1) It is homozygous for an allele in which the base at the position corresponding to position 40 of SEQ ID NO: 2 is T (hereinafter, may be referred to as "genetic feature B-1 of the present invention”).
- (B-2) It is homozygous for an allele in which the base at the position corresponding to position 44 of SEQ ID NO: 3 is T (hereinafter, may be referred to as "genetic feature B-2 of the present invention”).
- (B-3) It is homozygous for an allele in which the base at the position corresponding to position 48 of SEQ ID NO: 4 is C (hereinafter, may be referred to as "genetic feature B-3 of the present invention”).
- (B-4) Homozygous for alleles lacking the portion corresponding to positions 55 to 72 of SEQ ID NO: 5 (hereinafter, may be referred to as "genetic feature B-4 of the present invention”). ..
- the stevia plant of the present invention is heterozygous for an allele in which the base at the position corresponding to position 49 of SEQ ID NO: 6 is A (hereinafter, "genetic feature of the present invention”). It may be referred to as "C”).
- the stevia plant of the present invention is homozygous for an allele in which the base at the position corresponding to position 49 of SEQ ID NO: 6 is A (hereinafter, “genetic feature of the present invention”). It may be referred to as "D").
- the Stevia plant of the present invention means the genetic feature X of the present invention (hereinafter, unless otherwise specified, means at least one of the genetic features X-1 to X-3 of the present invention). And genetic feature A.
- the Stevia plant of the present invention comprises the genetic features X and B of the present invention (hereinafter, unless otherwise specified, the genetic features B-1 to B-4 of the present invention. Means at least one).
- the Stevia plant of the present invention has the genetic feature X and the genetic feature C or D of the present invention.
- the Stevia plant of the present invention has the genetic feature X, the genetic feature A and the genetic feature B of the present invention.
- the Stevia plant of the present invention has a genetic feature X, a genetic feature A and a genetic feature C or D of the present invention.
- the Stevia plant of the present invention has the genetic feature X, the genetic feature B, and the genetic feature C or D of the present invention.
- the Stevia plant of the present invention has all of the genetic features X, A, B and C or D of the present invention.
- the "position (or part) corresponding to” means a sequence existing in the genome when the same sequence as the reference sequence (for example, SEQ ID NOs: 1 to 6, 151 to 153, etc.) exists in the genome. It means a position or part in the middle (for example, 201st, 40th, 44th, 41st, 55-72th, 49th, 79th, 65th, 24th, etc.) and is the same as the reference sequence in the genome. When the sequence does not exist, it means a position or a part corresponding to a position or a part in the reference sequence in the sequence corresponding to the reference sequence in the genome.
- Whether or not a sequence equal to or equivalent to the reference sequence exists in the genome is determined by, for example, amplifying the genomic DNA of the target Stevia plant with a primer capable of amplifying the reference sequence by PCR and sequencing the amplification product. It can be determined by performing an alignment analysis between the obtained sequence and the reference sequence.
- Non-limiting examples of the sequence corresponding to the reference sequence include, for example, 60% or more, 70% or more, 75% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more with respect to the reference sequence.
- a base sequence having the above can be mentioned.
- the position or portion corresponding to the position or portion in the reference sequence in the sequence corresponding to the reference sequence in the genome can be determined in consideration of the base sequences before and after the position or portion in the reference sequence. For example, by aligning the reference sequence with the sequence corresponding to the reference sequence in the genome, the position or part corresponding to the position or part in the reference sequence in the sequence corresponding to the reference sequence in the genome can be determined. it can.
- the genome of the Stevia plant has a portion having the same base sequence as SEQ ID NO: 1.
- the "position corresponding to the 201st position of SEQ ID NO: 1" is the 201st position from the 5'side of the portion having the same base sequence as SEQ ID NO: 1 in the genome.
- the genome of the Stevia plant is not the same as SEQ ID NO: 1 but has a portion consisting of a base sequence corresponding thereto, the genome does not have a portion consisting of the same base sequence as SEQ ID NO: 1.
- the "position corresponding to the 201st position of SEQ ID NO: 1" does not necessarily correspond to the 201st position from the 5'side of the portion corresponding to the SEQ ID NO: 1, but the base sequence before and after the 201st position of the SEQ ID NO: 1 is used. With consideration, the "position corresponding to position 201 of SEQ ID NO: 1" in the genome of such a Stevia plant can be identified. For example, by aligning the base sequence of the portion corresponding to SEQ ID NO: 1 in the genome of the Stevia plant with the base sequence of SEQ ID NO: 1, the "position corresponding to position 201 of SEQ ID NO: 1" in the genome of the Stevia plant is specified. can do.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 1" is, for example, 60% or more, 70% or more, 75% or more, 80% or more, 81% or more, 82% or more, etc. 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% 96% or more, 97% or more, 98% or more, 98.1% or more, 98.4% or more, 98.7% or more, 99% or more, 99.2% or more, 99.5% or more or 99.4% or more. It means a portion consisting of a base sequence having 8% or more sequence identity.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 1" includes a forward primer that hybridizes to the complementary sequence of the portion 15 to 25 bases long from the 5'end of SEQ ID NO: 1 and a SEQ ID NO: It contains a portion of the Stevia plant genome that can be amplified by PCR with a reverse primer that hybridizes to a portion 15-25 bases long from the 3'end side of 1.
- the genetic feature A of the present invention has been described as an example, but the genetic features X (including the genetic features X-1 to X-3) and B (genetic features B-1 to B-1 to 3) of the present invention have been described. The same applies to C and D) (including B-4).
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 151" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 154 and a reverse primer containing the base sequence of SEQ ID NO: 155. Contains parts of the Stevia plant genome that can be amplified by.
- the "part consisting of the base sequence corresponding to SEQ ID NO: 152" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 156 and a reverse primer containing the base sequence of SEQ ID NO: 157. Contains parts of the Stevia plant genome that can be amplified by.
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 153" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 158 and a reverse primer containing the base sequence of SEQ ID NO: 159. Contains parts of the Stevia plant genome that can be amplified by.
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 1" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 7 and a reverse primer containing the base sequence of SEQ ID NO: 8. Contains parts of the Stevia plant genome that can be amplified by.
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 2" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 9 and a reverse primer containing the base sequence of SEQ ID NO: 10. Contains parts of the Stevia plant genome that can be amplified by.
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 3" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 11 and a reverse primer containing the base sequence of SEQ ID NO: 12. Contains parts of the Stevia plant genome that can be amplified by.
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 4" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 13 and a reverse primer containing the base sequence of SEQ ID NO: 14. Contains parts of the Stevia plant genome that can be amplified by.
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 5" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 15 and a reverse primer containing the base sequence of SEQ ID NO: 16. Contains parts of the Stevia plant genome that can be amplified by.
- the "portion consisting of the base sequence corresponding to SEQ ID NO: 6" includes, for example, PCR using a forward primer containing the base sequence of SEQ ID NO: 17 and a reverse primer containing the base sequence of SEQ ID NO: 18. Contains parts of the Stevia plant genome that can be amplified by.
- the "allele in which the base at position 79 of SEQ ID NO: 151 is C” comprises the base sequence of SEQ ID NO: 160, 161 or 162.
- the "allele in which the base at position 65 of SEQ ID NO: 152 is T” comprises the base sequence of SEQ ID NO: 163, 164 or 165.
- the "allele in which the base at position corresponding to position 24 of SEQ ID NO: 153 is T” comprises the base sequence of SEQ ID NO: 166, 167 or 168.
- the "allele in which the base at position 201 of SEQ ID NO: 1 is A” comprises the base sequence of SEQ ID NO: 19, 20 or 21.
- the "allele in which the base at position corresponding to position 40 of SEQ ID NO: 2 is T” comprises the base sequence of SEQ ID NO: 22, 23 or 24.
- the "allele in which the base at position corresponding to position 44 of SEQ ID NO: 3 is T” comprises the base sequence of SEQ ID NO: 25, 26 or 27.
- the "allele in which the base at position 48 of SEQ ID NO: 4 is C” comprises the base sequence of SEQ ID NO: 28, 29 or 30.
- the "allele lacking the portion corresponding to positions 55-72 of SEQ ID NO: 5" comprises the nucleotide sequence of SEQ ID NO: 31, 32 or 33.
- the "allele in which the base at position 49 of SEQ ID NO: 6 is A" comprises the base sequence of SEQ ID NO: 34, 35 or 36.
- the above genetic features are PCR method, TaqMan PCR method, sequencing method, microarray method, invader method, TILLING method, RAD (random amplified polymorphic DNA) method, restriction enzyme fragment length polymorphism (RFLP) method, PCR-SCSP method.
- AFLP amplified fragment length polymorphism
- SSLP simple sequence length polymorphism
- CAPS cleaved amplified polymorphic sequence
- dCAPS derived cleaved amplified polymorphic sequence
- ASO allele-specific oligonucleotide
- ARMS Modulator concentration gradient gel electrophoresis
- CCM chemical cleavage of mismatch
- DOL DOL method
- MALDI-TOF / MS method MALDI-TOF / MS method
- TDI method padlock probe method
- molecular beacon method DASH (dynamic allele specific hybridization) Method
- UCAN method ECA method
- PINPOINT method PROBE (primer oligonucleotide) method
- VSET very short extension
- the genetic features of the invention can be detected with the following primer set and restriction enzyme combinations.
- a forward primer having the nucleotide sequence shown in SEQ ID NO: 169 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 170 are used for the genomic DNA of the candidate plant.
- the obtained PCR product about 166 bp length, for example, SEQ ID NO: 171
- the restriction enzyme AluI the length was about 120 bp (for example, SEQ ID NO: 172) and about 46 bp length (for example, SEQ ID NO: 171).
- the band of SEQ ID NO: 173 is generated.
- PCR amplification gives, for example, a PCR product of SEQ ID NO: 174 (about 166 bp long), whereas even if AluI restriction enzyme treatment is performed on it, only a band of about 166 bp long (eg, SEQ ID NO: 174) can be obtained. If so, the candidate plant does not have the genetic feature X-1.
- a forward primer having the nucleotide sequence shown in SEQ ID NO: 169 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 175 are used for the genomic DNA of the candidate plant.
- the obtained PCR product about 340 bp length, for example, SEQ ID NO: 176
- the restriction enzyme Tsp45I the length was about 225 bp (for example, SEQ ID NO: 177) and about 115 bp length (for example, SEQ ID NO: 176).
- the band of SEQ ID NO: 178) is generated.
- PCR amplification gives, for example, a PCR product of SEQ ID NO: 179 (about 340 bp length), whereas Tsp45I restriction enzyme treatment gives only a band of about 340 bp length (eg, SEQ ID NO: 179). If so, the candidate plant does not have the genetic feature X-2.
- a forward primer having the nucleotide sequence shown in SEQ ID NO: 169 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 180 are used for the genomic DNA of the candidate plant.
- the obtained PCR product (about 293 bp length, for example, SEQ ID NO: 181) was treated with the restriction enzyme NlaIII, the length was about 259 bp (for example, SEQ ID NO: 182) and about 34 bp length (for example, SEQ ID NO: 181).
- the band of SEQ ID NO: 183 is generated.
- PCR amplification gives, for example, a PCR product of SEQ ID NO: 184 (about 293 bp length), whereas Nla III restriction enzyme treatment gives only a band of about 293 bp length (eg, SEQ ID NO: 184). If so, the candidate plant does not have the genetic feature X-3.
- PCR is performed on the genomic DNA of the candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 37 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 38.
- amplification was performed and the obtained PCR product (about 196 bp length, for example, SEQ ID NO: 39) was treated with the restriction enzyme HPy188I, a band having a length of about 96 bp (for example, SEQ ID NO: 41) and a band having a length of about 100 bp (eg, SEQ ID NO: 41) were treated.
- SEQ ID NO: 42 occurs.
- PCR amplification gives, for example, a PCR product of SEQ ID NO: 40 (about 196 bp in length), and restriction enzymes Hpy188I use restriction enzymes of about 43 bp (eg, SEQ ID NO: 43) and about 57 bp (eg, SEQ ID NO: 44).
- restriction enzymes Hpy188I use restriction enzymes of about 43 bp (eg, SEQ ID NO: 43) and about 57 bp (eg, SEQ ID NO: 44).
- a forward primer having the nucleotide sequence shown in SEQ ID NO: 45 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 46 are used for the genomic DNA of the candidate plant. Even if the obtained PCR product (about 297 bp length, for example, SEQ ID NO: 47) is treated with a KpnI restriction enzyme, only a band with a length of about 297 bp (for example, SEQ ID NO: 47) can be obtained.
- PCR amplification yields, for example, a PCR product of SEQ ID NO: 48 (approximately 297 bp in length) and restriction enzyme KpnI produces a restriction enzyme-treated product of approximately 258 bp (eg, SEQ ID NO: 49), the candidate plant. Does not have the genetic feature B-1.
- a forward primer having the nucleotide sequence shown in SEQ ID NO: 50 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 51 are used for the genomic DNA of the candidate plant. Even if the obtained PCR product (about 383 bp length, for example, SEQ ID NO: 52) is treated with an XbaI restriction enzyme, only a band with a length of about 383 bp (for example, SEQ ID NO: 52) can be obtained.
- the PCR product of SEQ ID NO: 53 (for example, about 297 bp length) is obtained by PCR amplification and the restriction enzyme treatment product of about 344 bp length (for example, SEQ ID NO: 54) is produced by the restriction enzyme XbaI, the candidate plant thereof.
- the body does not have the genetic feature B-2.
- a forward primer having the nucleotide sequence shown in SEQ ID NO: 55 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 56 are used for the genomic DNA of the candidate plant. Even if PCR amplification is performed and the obtained PCR product (about 390 bp length, for example, SEQ ID NO: 57) is treated with an AflII restriction enzyme, only a band with a length of about 390 bp (for example, SEQ ID NO: 57) is obtained.
- the candidate plant is used. Does not have the genetic feature B-3.
- PCR is performed on the genomic DNA of the candidate plant using a forward primer having the nucleotide sequence shown in SEQ ID NO: 60 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 61.
- Amplification yields only about 140 bp of PCR product (eg, SEQ ID NO: 62).
- the candidate plant does not have the genetic feature B-4.
- a forward primer having the nucleotide sequence shown in SEQ ID NO: 64 and a reverse primer having the nucleotide sequence shown in SEQ ID NO: 65 are used for the genomic DNA of the candidate plant.
- the obtained PCR product (about 367 bp length, for example, SEQ ID NO: 66) was treated with the restriction enzyme SpeI, it was about 367 bp length (for example, SEQ ID NO: 66) and about 321 bp length (for example, sequence).
- the band number 68) is obtained.
- PCR amplification yields, for example, a PCR product of SEQ ID NO: 67 (approximately 367 bp in length) and restriction enzyme SpI produces only a restriction enzyme-treated product of approximately 367 bp in length (eg, SEQ ID NO: 67), the candidate plant.
- the body has no genetic features C and D. With respect to the bp length, "about” means ⁇ 5 bp.
- the restriction enzyme treatment can be performed according to the conditions recommended by the distributor of each restriction enzyme used.
- the pollen-forming ability can be evaluated, for example, by any known method or the method described in Example 6.
- Non-limiting examples of the pollen forming ability evaluation method include, for example, the following methods. (1) Flower the test Stevia plant. (2) Count the number of pollen contained in the flowered flower.
- the test Stevia plant may be cultivated alone or together with the wild-type Stevia plant (control) in the same environment. When cultivated alone, the number of pollen formed on the test Stevia plant and the number of pollen formed on the wild-type Stevia plant cultivated under the same conditions (for example, in the literature and It may include a step of comparing with (based on data obtained in separate experiments).
- the above evaluation method compares the number of pollen formed on the test Stevia plant with the number of pollen formed on the wild-type Stevia plant cultivated together.
- the process may be included.
- Flowering can be induced under short-day conditions.
- the short-day condition is that the dark period is more than 10 hours, preferably 11 hours or more.
- the specific length of the dark period may be, for example, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, and the like.
- pollen counting is performed with the flowers fully bloomed.
- the plants of the invention contain 3% or more RebD per unit mass of dried leaves.
- a predetermined mass of dried leaves eg, 50 mg
- the ratio of RebD per unit mass of dried leaves in this embodiment is not limited, for example, 3.0% or more, 3.1% or more, 3.2% or more, 3.3% or more, 3.4%. Above, 3.5% or more, 3.6% or more, 3.7% or more, 3.8% or more, 3.9% or more, 4.0% or more, 4.1% or more, 4.2% or more, 4.3% or more, 4.4% or more, 4.5% or more, 4.6% or more, 4.7% or more, 4.8% or more, 4.9% or more, 5.0% or more, 5.
- the dried leaf means a leaf having a water content reduced to 3 to 4% by weight by drying the fresh leaf of the Stevia plant of the present invention.
- the plant of the present invention contains 2.6% or more RebD and 0.4% or more RebM per unit mass of dried leaves.
- the ratio of RebD and RebM per unit mass of dried leaves in this embodiment is not limited when (Ratio of RebD: Ratio of RebM) is defined as, for example, (2.6% or more: 0.4% or more).
- the upper limit of the ratio of RebD per unit mass of dried leaves is not particularly limited, but may be, for example, 20%, 15%, 10%, etc., and the upper limit of the ratio of RebM is also not particularly limited, but 10%, 5%. It may be 3% or the like. As shown in the examples, genetic features A to D are highly relevant to this aspect.
- the plant of the present invention contains RebD and RevM in total of 3.7% or more per unit mass of dried leaves.
- the total mass of RebD and RevM contained in a predetermined mass of dried leaves is 3.7% by mass or more (for example, 1.85 mg or more).
- the total ratio of RebD and RevM per unit mass of dried leaves in this embodiment is not limited, for example, 3.7% or more, 3.8% or more, 3.9% or more, 4.0% or more. 4.1% or more, 4.2% or more, 4.3% or more, 4.4% or more, 4.5% or more, 4.6% or more, 4.7% or more, 4.8% or more, 4.
- the plant of the present invention has a total mass ratio of RebD and RebM of 37.8% or more with respect to total steviol glycoside (TSG).
- TSG total steviol glycoside
- the total mass of RebD and RevM contained in a leaf for example, dried leaf or fresh leaf
- RebD + RebM / TSG% as a ratio to the total mass of steviol glycosides obtained from the leaf, it is RebD + RebM.
- the value of / TSG is 37.8% or more.
- the values of RebD + RebM / TSG in this embodiment are not limited, for example, 37.8% or more, 37.9% or more, 38.0% or more, 38.1% or more, 38.2% or more, 38.3.
- the upper limit of the mass ratio of RebD + RevM to the total steviol glycoside is not particularly limited, but may be, for example, 85%, 75%, 65%, 55% or the like. As shown in the examples, genetic features A to D are highly relevant to this aspect.
- TSG is a general term for measurable steviol glycosides, and does not include unknown steviol glycosides or steviol glycosides present in an amount below the detection limit.
- the total steviol glycosides are RebA, RebB, RebD, RebE, RebF, RebI, RebJ, RebK, RebM, RebN, RebO, RebQ, RebR, Zulcoside A, Rubusoside, Steviolmonoside, Steviolbioside and Any combination of two or more selected from the group consisting of steviosides.
- the total steviol glycoside comprises RebA, RebB, RebM, RebD, RevF, RebM and stevioside
- the total steviol glycoside is RebA, RebB, RebM, RebD, It may consist of RebF, RebM, RebN, RebO and stevioside.
- the total steviol glycoside comprises RebA, RebB, RebC, RebD, RebF, RebM, RebN and RebO.
- the plant of the present invention contains 0.2% or more of RebM per unit mass of dried leaves.
- the ratio of RevM per unit mass of dried leaves in this embodiment is not limited, for example, 0.20% or more, 0.25% or more, 0.30% or more, 0.35% or more, 0.40%.
- 0.45% or more 0.50% or more, 0.55% or more, 0.60% or more, 0.65% or more, 0.70% or more, 0.75% or more, 0.80% or more, 0.85% or more, 0.90% or more, 0.95% or more, 1.00% or more, 1.05% or more, 1.10% or more, 1.15% or more, 1.20% or more 1. It may be 25% or more, 1.30% or more, 1.35% or more, 1.40% or more, 1.45% or more, preferably 0.4% or more.
- the upper limit of the ratio of RevM per unit mass of dried leaves is not particularly limited, but may be, for example, 15%, 10%, 5% or the like. As shown in the examples, genetic feature B is highly relevant to this aspect.
- the plant of the present invention has a mass ratio of RevM to total steviol glycoside of 2% or more.
- a mass ratio of RevM to total steviol glycoside of 2% or more.
- This is, for example, when the mass of RebM contained in a leaf (for example, dried leaf or fresh leaf) is expressed in RebM / TSG% as a ratio to the total mass of steviol glycosides obtained from the leaf, it is RebM / TSG. It means that the value is 2% or more.
- the value of RebM / TSG in this embodiment is not limited, for example, 2% or more, 2.5% or more, 3% or more, 3.5% or more, 4% or more, 4.5% or more, 5% or more.
- the upper limit of the mass ratio of RevM to the total steviol glycoside is not particularly limited, but may be, for example, 50%, 45%, 40%, 35% or the like. As shown in the examples, genetic feature B is highly relevant to this aspect.
- the plant of the present invention is a wild-type Stevia species when the amount (g) of rebaugioside M contained in 100 g of leaves (for example, dried leaves or fresh leaves) of a wild-type Stevia plant is 100%.
- a wild-type Stevia species when the amount (g) of rebaugioside M contained in 100 g of leaves (for example, dried leaves or fresh leaves) of a wild-type Stevia plant is 100%.
- the plant of the present invention contains 1% or more of RebD per unit mass of dried leaves.
- the ratio of RebD per unit mass of dried leaves in this embodiment is not limited, for example, 1.00% or more, 1.05% or more, 1.10% or more, 1.15% or more, 1.20%.
- 1.25% or more 1.30% or more, 1.35% or more, 1.40% or more, 1.45% or more, 1.50% or more, 1.55% or more, 1.60% or more, 1.65% or more, 1.70% or more, 1.75% or more, 1.80% or more, 1.85% or more, 1.90% or more, 1.95% or more, 2.00% or more, 2.
- the plant of the present invention has a lower limit of the value of RevM / RevD of 0.2 or more when the content of RevM and RevD in the leaves (for example, dried leaves or fresh leaves) is expressed by the ratio of RevM / RevD. , 0.3 or more, 0.4 or more, 0.5 or more, 0.6 or more, 0.8 or more, 1.0 or more.
- the upper limit of the RebM / RebD value is 0.3 or less, 0.4 or less, 0.5 or less, 0.6 or less, 0.8 or less, 1.0 or less, 1.1 or less, 1.2 or less. Is.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit value exceeds the lower limit value, but is preferably 0.2 or more and 1.2 or less, or 0.6 or more and 1.1 or less. As shown in the examples, genetic feature B is highly associated with this aspect.
- the plant of the present invention is (RebD + RevM) when the content of RevM and RevD in leaves (eg, dried or fresh leaves) is expressed as (RebD + RevM) / TSG% as a ratio to the total amount of steviol glycosides. ) /
- the lower limit of the TSG value is 14% or more, 16% or more, 18% or more, 20% or more, 22% or more, 24% or more, 26% or more, 28% or more, 30% or more, 32% or more, 34%. These are 36% or more and 38% or more.
- the upper limit of the value of (RebD + RevM) / TSG is 18% or less, 20% or less, 22% or less, 24% or less, 26% or less, 28% or less, 30% or less, 32% or less, 34% or less, 36. % Or less, 38% or less, 40% or less.
- the combination of the lower limit and the upper limit is not particularly limited as long as the upper limit value exceeds the lower limit value, but is preferably 14% or more and 40% or less, or 16% or more and 40% or less.
- genetic feature B is highly associated with this aspect.
- RevD and RevM are extracted in the form of an extract by reacting the fresh or dried leaves of the plant of the present invention with an appropriate solvent (aqueous solvent such as water or organic solvent such as alcohol, ether and acetone).
- aqueous solvent such as water or organic solvent such as alcohol, ether and acetone.
- ethyl acetate and other organic solvents water gradient, high performance liquid chromatography (HPLC), gas chromatography, time-of-flight mass analysis (Time-).
- RebD can be purified by using known methods such as of-Flight mass spectrometry (TOF-MS) and ultra (High) Performance Liquid Chromatography (UPLC).
- RevD or RevM can be measured by the method described in Ohta et al. Or WO2010 / 038911 described above, or by the method described in Examples described later. Specifically, it can be measured by sampling fresh leaves from the Stevia plant of the present invention and performing LC / MS-MS.
- the plant body of the present invention includes not only the whole plant body but also plant organs (for example, leaves, petals, stems, roots, seeds, etc.), plant tissues (for example, epidermis, phloem, parenchyma, xylem, vascular bundle, fence shape). It may include tissues, spongy tissues, etc.) or various forms of plant cells (eg, suspended cultured cells), protoplasts, leaf sections, callus, and the like. Further, the leaves may be the dried leaves described above.
- the plant body of the present invention may also include tissue culture or plant culture cells. This is because plants can be regenerated by culturing such tissue cultures or plant culture cells.
- tissue culture or plant culture cell of the plant body of the present invention include embryos, meristem cells, pollen, leaves, roots, root tips, petals, protoplasts, leaf sections and callus. It is not limited.
- the present invention comprises a step of crossing the Stevia plant of the present invention with a second Stevia plant, which has a lower pollen forming ability than the wild type. (Hereinafter, it may be referred to as "the method for producing the present invention").
- the “Stevia plant having a lower pollen-forming ability than the wild type” produced by this method has the same phenotype and genetic properties as the plant of the present invention.
- the pollen-forming ability, the range of RebD and RevM contents, etc. in the plant obtained by the production method of the present invention are as described above for the plant of the present invention.
- the plant obtained by the production method of the present invention has the genetic feature X of the present invention. In one aspect, the plant obtained by the production method of the present invention has the genetic feature A of the present invention. In another aspect, the plant obtained by the production method of the present invention has the genetic feature B of the present invention. In another aspect, the plant obtained by the production method of the present invention has the genetic features C or D of the present invention. In a preferred embodiment, the plant obtained by the production method of the present invention has the genetic feature X and the genetic feature A of the present invention. In another preferred embodiment, the plant obtained by the production method of the present invention has the genetic feature X and the genetic feature B of the present invention.
- the plant obtained by the production method of the present invention has the genetic feature X and the genetic feature C or D of the present invention.
- the plant obtained by the production method of the present invention has the genetic feature X, the genetic feature A, and the genetic feature B of the present invention.
- the plant obtained by the production method of the present invention has the genetic feature X, the genetic feature A, and the genetic feature C or D of the present invention.
- the plant obtained by the production method of the present invention has the genetic feature X, the genetic feature B, and the genetic feature C or D of the present invention.
- the plant obtained by the production method of the present invention has all of the genetic features X, A, B and C or D of the present invention.
- crossing means that the plant body (first generation (S1)) of the present invention is crossed with the second plant body (S1), and the child plant body (the present invention) is crossed. It means to obtain a plant body (second generation (S2)) produced by the production method of.
- second generation (S2)) produced by the production method of.
- Back crossing means the plant body of the present invention and the second.
- the offspring plant (S2) born between the plant and the plant is further crossed with the plant of the present invention (that is, the plant having the genetic characteristics of the present invention) (S1) to carry out the genetic characteristics of the present invention. It is a method of producing a plant having the same.
- the second plant (S1) used in the production method of the present invention has the same phenotype and genetic properties as the plant of the present invention, it is substantially. It becomes a crossing back to.
- the plant of the present invention can be produced by self-fertilization.
- Self-propagation can be carried out by self-pollinating the stamen pollen of the plant of the present invention to the pistil of the plant of the present invention.
- the plant produced by the production method of the present invention has the same phenotype and genetic properties as the plant of the present invention, the plant produced by the production method of the present invention is further referred to as a third Stevia plant. It is also possible to produce a Stevia plant having a phenotype equivalent to that of the plant of the present invention by crossing with.
- the plant body of the present invention can also be produced by regenerating the plant body by culturing the tissue culture or plant culture cells described above.
- the culture conditions are the same as those for culturing wild-type stevia plant tissue cultures or plant culture cells, and are known (Protocols for In Vitro cultures and secondary metabolite analysis of aromatic and medical plants, Method in molecular biology, vo. 1391, pp113-123).
- the plant of the present invention can be produced by introducing a mutation of the present invention into the genome of a Stevia plant.
- the mutation may be introduced by a gene recombination method or a non-genetically recombinant method.
- An example of a "non-genetically modified method" is a method of inducing a mutation in a gene of a host cell (or a host plant) without introducing a foreign gene.
- Such a method includes a method of acting a mutagen of plant cells. Examples of such mutagens include ethyl methanesulfonic acid (EMS) and sodium azide.
- EMS ethyl methanesulfonic acid
- ethyl methanesulfonic acid is 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%. , 0.9%, 1.0% and the like can be treated with plant cells.
- the processing time is 1 to 48 hours, 2 to 36 hours, 3 to 30 hours, 4 to 28 hours, 5 to 26 hours, and 6 to 24 hours.
- the treatment procedure itself is known, it can be carried out by immersing the water-absorbed seeds that have undergone the water-absorbing process in a treatment solution containing a mutagen at the above concentration for the above-mentioned treatment time.
- a method of irradiating plant cells with radiation such as X-rays, ⁇ -rays, and ultraviolet rays or light rays can be used.
- cells irradiated with an appropriate ultraviolet irradiation amount can be cultured in a selective medium or the like, and then cells, callus, or plants having the desired trait can be selected. ..
- the irradiation intensity at that time was 0.01 to 100 Gr, 0.03 to 75 Gr, 0.05 to 50 Gr, 0.07 to 25 Gr, 0.09 to 20 Gr, 0.1 to 15 Gr, 0.1 to 10 Gr, 0.
- the irradiation distance is 1 cm to 200 m, 5 cm to 100 m, 7 cm to 75 m, 9 cm to 50 m, 10 cm to 30 m, 10 cm to 20 m, 10 cm to 10 m, and the irradiation time is 1 minute to 2 Year, 2 minutes to 1 year, 3 minutes to 0.5 years, 4 minutes to 1 month, 5 minutes to 2 weeks, 10 minutes to 1 week.
- the intensity, distance and time of irradiation vary depending on the radiation type and the state (cell, callus, plant) to be irradiated, but can be appropriately adjusted by those skilled in the art.
- plant cells may be mutated during culture, so it is preferable to return them to individual plants for more stable trait maintenance.
- Plants having a plurality of different genetic characteristics of the present invention can also be produced by crossing plants having different genetic characteristics of the present invention.
- a plant having the genetic features X and A of the present invention can be obtained by crossing a plant having the genetic features X of the present invention with a plant having the genetic features A of the present invention. Can be done.
- a plant having the genetic features A and C or D, a plant having the genetic features B and C or D of the present invention, and the like can also be obtained by the same crossing.
- the plant having the genetic features X, A, and B of the present invention includes a plant having the genetic features X and A of the present invention and a plant having the genetic features B of the present invention.
- a plant having the genetic features X, B and C or D of the present invention, a plant having the genetic features A, B and C or D of the present invention, and the like can also be obtained by the same crossing.
- the crossing is preferably carried out for two or more generations, but when the genetic characteristics are heterozygous or the like, a plant having a desired combination of genetic characteristics may be obtained in one generation.
- the present invention comprises the step of detecting the presence and / or absence of at least one of the genetic features X, A, B, C and D of the present invention from the genome of a test plant.
- the screening method of the present invention is a method for screening a Stevia plant having a low level.
- the genetic feature to be detected is the genetic feature X of the present invention. In another embodiment, the genetic feature to be detected is the genetic feature A of the present invention. In another embodiment, the genetic feature to be detected is the genetic feature B of the present invention. In another embodiment, the genetic feature to be detected is the genetic feature C of the present invention. In another embodiment, the genetic feature to be detected is the genetic feature D of the present invention. In a preferred embodiment, the genetic features to be detected are the genetic features X and A of the present invention. In another preferred embodiment, the genetic features to be detected are the genetic features X and B of the present invention. In another preferred embodiment, the genetic features to be detected are the genetic features X and the genetic features C or D of the present invention.
- the genetic features to be detected are the genetic feature X, the genetic feature A, and the genetic feature B of the present invention. In another preferred embodiment, the genetic features to be detected are the genetic feature X, the genetic feature A, and the genetic feature C or D of the present invention. In another preferred embodiment, the genetic features to be detected are the genetic feature X, the genetic feature B, and the genetic feature C or D of the present invention. In a more preferred embodiment, the genetic features to be detected are all of the genetic features X, A, B and C or D of the present invention.
- the screening method of the present invention may further include a step of selecting a plant from which the presence of at least one of the above genetic features has been detected from among the test plants.
- X-1 An allele in which the base at the position corresponding to position 79 of SEQ ID NO: 151 is C (for example, an allele containing the base sequence of SEQ ID NO: 160, 161 or 162).
- X-2) An allele in which the base at the position corresponding to position 65 of SEQ ID NO: 152 is T (for example, an allele containing the base sequence of SEQ ID NO: 163, 164 or 165).
- X-3) An allele in which the base at the position corresponding to the 24th position of SEQ ID NO: 153 is T (for example, an allele containing the base sequence of SEQ ID NO: 166, 167 or 168).
- (B-3) An allele in which the base at the position corresponding to position 48 of SEQ ID NO: 4 is C (for example, an allele containing the base sequence of SEQ ID NO: 72).
- (B-4) An allele in which the portion corresponding to positions 55 to 72 of SEQ ID NO: 5 is deleted (for example, an allele containing the base sequence of SEQ ID NO: 73), and (C) Corresponding to position 49 of SEQ ID NO: 6.
- An allele in which the base at the position is A (for example, an allele containing the base sequence of SEQ ID NO: 74) Detection of the presence of an allele selected from the group consisting of and / or (X-1) An allele in which the base at the position corresponding to position 79 of SEQ ID NO: 151 is T (for example, an allele containing the base sequence of SEQ ID NO: 185, 186 or 187). (X-2) An allele in which the base at the position corresponding to position 65 of SEQ ID NO: 152 is A (for example, an allele containing the base sequence of SEQ ID NO: 188, 189 or 190).
- (X-3) An allele in which the base at the position corresponding to the 24th position of SEQ ID NO: 153 is A (for example, an allele containing the base sequence of SEQ ID NO: 191, 192 or 193).
- (B-2) An allele in which the base at the position corresponding to the 40th position of SEQ ID NO: 3 is C (for example, an allele containing the base sequence of SEQ ID NO: 3).
- (B-3) An allele in which the base at the position corresponding to the 48th position of SEQ ID NO: 4 is G (for example, an allele containing the base sequence of SEQ ID NO: 4).
- (B-4) An allele in which the portion corresponding to positions 55 to 72 of SEQ ID NO: 5 is not deleted (for example, an allele containing the base sequence of SEQ ID NO: 5), and (c) Corresponding to position 49 of SEQ ID NO: 6.
- An allele in which the base at the position is C (for example, an allele containing the base sequence of SEQ ID NO: 6) It can be determined by the detection of the absence of an allele selected from the group consisting of.
- (B-3) An allele in which the base at the position corresponding to position 48 of SEQ ID NO: 4 is C (for example, an allele containing the base sequence of SEQ ID NO: 72).
- (B-4) An allele in which the portion corresponding to positions 55 to 72 of SEQ ID NO: 5 is deleted (for example, an allele containing the base sequence of SEQ ID NO: 73), and (C) Corresponding to position 49 of SEQ ID NO: 6.
- An allele in which the base at the position is A (for example, an allele containing the base sequence of SEQ ID NO: 74) Detection of the absence of alleles selected from the group consisting of and / or (X-1) An allele in which the base at the position corresponding to position 79 of SEQ ID NO: 151 is T (for example, an allele containing the base sequence of SEQ ID NO: 185, 186 or 187). (X-2) An allele in which the base at the position corresponding to position 65 of SEQ ID NO: 152 is A (for example, an allele containing the base sequence of SEQ ID NO: 188, 189 or 190).
- (X-3) An allele in which the base at the position corresponding to the 24th position of SEQ ID NO: 153 is A (for example, an allele containing the base sequence of SEQ ID NO: 191, 192 or 193).
- (B-2) An allele in which the base at the position corresponding to the 40th position of SEQ ID NO: 3 is C (for example, an allele containing the base sequence of SEQ ID NO: 3).
- (B-3) An allele in which the base at the position corresponding to the 48th position of SEQ ID NO: 4 is G (for example, an allele containing the base sequence of SEQ ID NO: 4).
- (B-4) An allele in which the portion corresponding to positions 55 to 72 of SEQ ID NO: 5 is not deleted (for example, an allele containing the base sequence of SEQ ID NO: 5), and (c) Corresponding to position 49 of SEQ ID NO: 6.
- An allele in which the base at the position is C (for example, an allele containing the base sequence of SEQ ID NO: 6) It can be determined by detecting the presence of an allele selected from the group consisting of.
- Specific examples of the method for detecting the genetic features of the present invention include PCR method, TaqMan PCR method, sequencing method, microarray method, invader method, TILLING method, RAD method, RFLP method, PCR-SCSP method, AFLP method, and SSLP method.
- a primer such that the 3'end portion has a sequence complementary to the polymorphic site of the present invention.
- the primer designed in this way when the sample to be the template has a polymorphism, the primer completely hybridizes to the template, so that the polymerase extension reaction proceeds, but the template has the mutation of the present invention. Otherwise, the nucleotide at the 3'end of the primer will mismatch with the template and no extension reaction will occur. Therefore, if PCR amplification is performed using such a primer, the amplification product is analyzed by agarose gel electrophoresis or the like, and an amplification product of a predetermined size can be confirmed, the template as a sample has a mutation.
- the primer sequence is designed so that the polymorphism of the present invention and the primer sequence do not overlap and the gene mutation of the present invention can be PCR-amplified, and the base sequence of the amplified nucleotide fragment is sequenced. Therefore, the genetic features of the present invention can be detected.
- PCR and agarose gel electrophoresis see: Sambrook, Fritsch and Maniatis, "Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press.
- the TaqMan PCR method is a method that utilizes a fluorescently labeled allele-specific oligo and a PCR reaction with Taq DNA polymerase (Livak, KJ Genet. Anal. 14, 143 (1999); Morris T. et al., J. . Clin.Microbiol. 34, 2933 (1996)).
- the sequencing method is a method of analyzing the presence or absence of mutation by amplifying a region containing a mutation by PCR and sequencing a DNA sequence using a Dye Terminator or the like (Sambrook, Fritsch and Maniatis described above).
- a DNA microarray is one in which one end of a nucleotide probe is fixed in an array on a support, and includes a DNA chip, a Gene chip, a microchip, a bead array, and the like. By using a probe containing a sequence complementary to the polymorphism of the present invention, the presence or absence of the polymorphism of the present invention can be comprehensively detected.
- DNA microarray assays such as DNA chips include the GeneChip assay (see Affymetrix; US Pat. Nos. 6,045,996, 5,925,525, and 5,858,659). GeneChip technology utilizes a miniaturized, high-density microarray of oligonucleotide probes attached to the chip.
- the invader method is a special method in which two types of reporter probes specific to each allele of a polymorphism such as SNP and one type of invader probe are hybridized to template DNA, and the structure of the DNA is recognized and cleaved.
- a combination of DNA cleavage by a Cleavase enzyme with endonuclease activity (Livak, KJ Biomol. Eng. 14, 143-149 (1999); Morris T. et al., J. Clin. Microbiol. 34, 2933). (1996); Lyamichev, V. et al., Science, 260, 778-783 (1993), etc.).
- the TILLING (Targeting Induced Local Lesions IN Genomes) method is a method for screening mutation mismatches in the genome of a mutated mutant population by PCR amplification and CEL I nuclease treatment.
- the genetic features X-1 of the invention are a primer set capable of amplifying a region containing the sequence set forth in any of SEQ ID NOs: 160-162, and SEQ ID NOs: 160-162, without limitation. Does not cleave the polynucleotides of SEQ ID NOs: 185 to 187 but not restriction enzymes (eg, AluI) or the polynucleotides of SEQ ID NOs: 160 to 162, but does not cleave the polynucleotides of SEQ ID NOs: 185 to 187. It can be detected by the CAPS method using a restriction enzyme.
- Non-limiting examples of primer sets include the following. Forward primer: ACGGTTTACACTCTCAGTCATTCC (SEQ ID NO: 169) Reverse primer: GCCAGTCATCATATAATCATCCACAA (SEQ ID NO: 170)
- the genetic features X-2 of the invention are a primer set capable of amplifying a region containing the sequence set forth in any of SEQ ID NOs: 163 to 165 and SEQ ID NOs: 163 to 165, without limitation. Does not cleave the polynucleotides of SEQ ID NOs: 188-190 but not restriction enzymes (eg, Tsp45I) or the polynucleotides of SEQ ID NOs: 163-165, but does not cleave the polynucleotides of SEQ ID NOs: 188-190. It can be detected by the CAPS method using a restriction enzyme.
- Non-limiting examples of primer sets include the following. Forward primer: ACGGTTTACACTCTCAGTCATTCC (SEQ ID NO: 169) Reverse primer: GTCGAGCTTACAAACCATTTACCA (SEQ ID NO: 175)
- the genetic feature X-3 of the present invention can be detected, without limitation, by the dCAPS method using the following primer sets and restriction enzymes.
- ⁇ Primer set A forward primer containing any contiguous 15 or more base sequences (eg, SEQ ID NO: 169) located 5'from position 257 of SEQ ID NO: 181 or 184, and a sequence selected from SEQ ID NOs: 180, 194 to 201.
- a primer set comprising a reverse primer containing a contiguous sequence 15-29 bases long from the 3'end.
- the primer sequence can be optimized within the range satisfying the above conditions.
- each of the above primers may have a length of 15 to 50 bases, a length of 18 to 48 bases, a length of 20 to 45 bases, a length of 30 to 65 bases, or the like.
- Restriction enzymes The restriction enzymes corresponding to each of SEQ ID NOs: 180 and 194 to 201 are shown below.
- the genetic feature X-3 of the present invention can be detected by the dCAPS method using the following primer set and restriction enzymes.
- the genetic feature A of the invention is a primer set capable of amplifying a region containing the sequence set forth in any of SEQ ID NOs: 19-21 and a poly of SEQ ID NOs: 19-21, without limitation.
- Restriction enzymes that cleave nucleotides but not polynucleotides of SEQ ID NOs: 75-77 or restriction enzymes that do not cleave polynucleotides of SEQ ID NOs: 19-21 but cleave polynucleotides of SEQ ID NOs: 75-77 (eg, Hpy188I) ) And can be detected by the CAPS method.
- Non-limiting examples of primer sets include the following. Forward primer: ATGGTTTGGGAATAGCTCTGTTGTT (SEQ ID NO: 37)
- Reverse primer AGAACTTTGTTCTTGAACCCTTG (SEQ ID NO: 38)
- the genetic feature B of the present invention can be detected without limitation by the dCAPS method or the like using the following primer set and restriction enzyme.
- B-1 A primer set containing a forward primer containing the nucleotide sequence shown in SEQ ID NO: 45 and a reverse primer containing the nucleotide sequence shown in SEQ ID NO: 46.
- B-2) A primer set containing a forward primer containing the nucleotide sequence shown in SEQ ID NO: 50 and a reverse primer containing the nucleotide sequence shown in SEQ ID NO: 51.
- (B-3) A primer set containing a forward primer containing the nucleotide sequence shown in SEQ ID NO: 55 and a reverse primer containing the nucleotide sequence shown in SEQ ID NO: 56, or (B-4) Forward containing the nucleotide sequence shown in SEQ ID NO: 60.
- the primer set is not limited to the one having the sequence of SEQ ID NO: 45, 46, 50, 51, 55, 56, 60 or 61.
- the primer set of SEQ ID NO: 45, 50, 55 or 60 Any sequence that has a sequence from the 3'end to 15 bases upstream (see the table below) may be used as a reverse primer from the 3'end to 15 bases upstream of SEQ ID NO: 46, 51, 56 or 61. Any one having the sequence of (see the table below) at the 3'end.
- Such primers may have a length of 15 to 50 bases and a length of 20 to 45 bases.
- the primer set is not limited to those having the sequence of SEQ ID NO: 45, 46, 50, 51, 55, 56, 60 or 61, for example, as a forward primer, any of SEQ ID NOs: 45, 50, 55, or 60. It may have or contain a sequence of 15 or more consecutive bases, and the reverse primer may have or contain any consecutive sequence of 15 or more bases in SEQ ID NO: 46, 51, 56 or 61. .. (B-1'') Primer comprising a forward primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 45 and a reverse primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 46.
- Primer comprising a forward primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 50 and a reverse primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 51.
- set, (B-3'') Primer comprising a forward primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 55 and a reverse primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 56.
- a set, or (B-4'') forward primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 60 and a reverse primer having or containing any contiguous 15 or more bases sequence in SEQ ID NO: 61.
- Such a primer may have a length of 15 to 50 bases, a length of 20 to 45 bases, or a length of 30 to 65 bases as long as the arbitrary continuous sequence of 15 bases or more is present at the 3'side terminal. Good.
- restriction enzymes to be combined with the above primers include the following.
- the genetic features C or D of the present invention can be detected by the dCAPS method using the following primer sets and restriction enzymes.
- ⁇ Primer set A sequence selected from SEQ ID NOs: 86 to 109, 150 located at the 3'end, and any contiguous sequence following the 28th to 5'side of SEQ ID NO: 6 added to the 5'end of the sequence by arbitrary selection.
- a sequence complementary to a forward primer containing eg, a contiguous sequence of arbitrary length
- any contiguous sequence of 20 or more bases located 3'from position 50 of SEQ ID NO: 6 eg, sequence.
- the primer sequence can be optimized within the range satisfying the above conditions.
- each of the above primers may have a length of 15 to 50 bases, a length of 18 to 48 bases, a length of 20 to 45 bases, a length of 30 to 65 bases, or the like.
- Restriction enzymes The restriction enzymes corresponding to each of SEQ ID NOs: 86 to 109 and 150 are shown below. In the following sequence, “R” represents A or G and “Y” represents C or T.
- the genetic features C or D of the present invention can be detected by the dCAPS method using the following primer sets and restriction enzymes.
- the screening method of the present invention may further include a step of evaluating the pollen-forming ability of the test Stevia plant in which the genetic features of the present invention have been detected.
- the evaluation of pollen forming ability is as described in the section of the plant body of the present invention.
- an individual having a low pollen-forming ability is selected and crossed with another Stevia plant to obtain a child plant.
- the screening method of the present invention may be applied to the body. Therefore, the screening method of the present invention may include one or more of the following steps.
- (Ii) A step of evaluating the pollen-forming ability of a test Stevia plant tissue in which the genetic features of the present invention have been detected. (Iii) A step of selecting an individual having a low pollen-forming ability from among the test Stevia plants in which the genetic features of the present invention have been detected. (Iv) A step of mating a selected individual with low pollen-forming ability with another Stevia plant, (V) A step of detecting the genetic feature of the present invention (for example, the genetic feature X of the present invention) from the genome of a child plant obtained by mating.
- the genetic feature of the present invention for example, the genetic feature X of the present invention
- the selected individuals with low pollen-forming ability are, for example, the top 50%, the top 40%, and the top 30% of the test Stevia plants in which the genetic features of the present invention have been detected, regarding the low pollen-forming ability. , Top 20%, Top 10%, Top 5%, Top 4%, Top 3%, Top 2%, Top 1%, and the like.
- other Stevia plants to be mated may or may not contain the genetic features of the present invention.
- steps (iv) to (vii) can be repeated a plurality of times. In this way, Stevia plants with lower pollen-forming ability can be screened.
- the test Stevia plant may be a natural plant or a non-genetically modified plant.
- the non-genetically modified plant is as described in the section of the plant of the present invention.
- the test Stevia plant may include a Stevia plant that has undergone mutagenesis treatment and a progeny plant thereof.
- the mutagenesis treatment is as described in the section of the plant body of the present invention, and includes treatment with a mutagenesis agent, treatment with radiation or light irradiation, and the like.
- the present invention also includes the primer set described above, for example, a primer set containing the forward primer of SEQ ID NO: 169 and the reverse primer of SEQ ID NO: 170, the forward primer of SEQ ID NO: 169 and the reverse primer of SEQ ID NO: 175.
- Primer set including, the primer set shown in Table 2, the primer set containing the forward primer of SEQ ID NO: 37 and the reverse primer of SEQ ID NO: 38, (B-1) to (B-4), (B).
- the primer set described in the above is provided.
- the present invention further relates to a primer set capable of amplifying a region having a base sequence selected from the group consisting of SEQ ID NOs: 151 to 153, 202 to 204, 1 to 6, 69 to 74 by PCR, for example, SEQ ID NO: 154.
- Primer set a primer set containing the nucleotide sequence of SEQ ID NO: 9, a reverse primer containing the nucleotide sequence of SEQ ID NO: 10, a forward primer containing the nucleotide sequence of SEQ ID NO: 11, and the nucleotide sequence of SEQ ID NO: 12
- the present invention provides a probe (hereinafter, may be referred to as "probe of the present invention") capable of detecting the presence and / or absence of a genetic feature of the present invention.
- the probe of the present invention may have a structure suitable for various detection methods in the presence and / or absence of the genetic features of the present invention.
- the probe of the present invention may contain a base sequence complementary to a portion of the genome containing the mutation site of the present invention.
- Non-limiting examples of such probes include those containing a base sequence selected from SEQ ID NOs: 160 to 168, 185 to 193, 19 to 36, 75 to 77, and 135 to 149.
- SEQ ID NOs: 160-168 and 19-36 are specific for alleles containing the mutations of the present invention, and SEQ ID NOs: 185-193, 75-77 and 135-149 contain the mutations of the present invention. Not specific to alleles.
- the presence of genetic features of the invention can be detected by detection of alleles containing mutations of the invention and / or non-detection of alleles not containing mutations of the invention, and the absence of genetic features of the invention is It can be detected by non-detection of alleles containing mutations of the present invention and / or detection of alleles not containing mutations of the present invention.
- the probe of the present invention preferably has a label.
- the probe of the present invention comprises a nucleotide sequence complementary to a nucleotide sequence selected from SEQ ID NOs: 160-168, 185-193, 19-36, 75-77, 135-149 and a label. Have.
- the present invention further comprises a primer set capable of amplifying a region containing the sequence set forth in any of SEQ ID NOs: 160 to 162, for example, a forward primer containing the nucleotide sequence of SEQ ID NO: 169 and a nucleotide sequence of SEQ ID NO: 170.
- a restriction enzyme eg, AluI
- a restriction enzyme eg, AluI
- Kits are provided that contain restriction enzymes that do not cleave the polynucleotides, but the polynucleotides of SEQ ID NOs: 185 to 187, such as screening kits.
- the present invention further comprises a primer set capable of amplifying a region containing the sequence set forth in any of SEQ ID NOs: 163 to 165, for example, a forward primer containing the nucleotide sequence of SEQ ID NO: 169 and the nucleotide sequence of SEQ ID NO: 175.
- a restriction enzyme eg, Tsp45I
- Kits are provided that contain restriction enzymes that do not cleave the polynucleotides, but the polynucleotides of SEQ ID NOs: 188-190, such as screening kits.
- the present invention is further selected from a forward primer containing any contiguous 15 or more base sequences (eg, SEQ ID NO: 169) located 5'from position 257 of SEQ ID NO: 181 and SEQ ID NOs: 180, 194 to 201.
- a forward primer containing any contiguous 15 or more base sequences eg, SEQ ID NO: 169 located 5'from position 257 of SEQ ID NO: 181 and SEQ ID NOs: 180, 194 to 201.
- a kit containing a reverse primer containing a contiguous sequence 15 to 25 bases long from the 3'end of the sequence, eg, the primer set shown in Table 2, and a corresponding restriction enzyme, eg, screening. Provide a kit for.
- the present invention further comprises a primer set capable of amplifying a region containing the sequence set forth in any of SEQ ID NOs: 19 to 21, such as a forward primer containing the nucleotide sequence of SEQ ID NO: 7 and a nucleotide sequence of SEQ ID NO: 8.
- Primer sets containing a combination with reverse primers and polynucleotides of SEQ ID NOs: 19-21 are cleaved, but polynucleotides of SEQ ID NOs: 75-77 are not cleaved. Restriction enzymes or polynucleotides of SEQ ID NOs: 19-21 are not cleaved.
- a kit containing a restriction enzyme eg, Hpy188I that cleaves the polynucleotides of SEQ ID NOs: 75 to 77, such as a screening kit, is provided.
- the present invention further comprises a group consisting of (B-1) to (B-4), (B-1') to (B-4') and (B-1'') to (B-4'') described above.
- Kits comprising any one or more primer sets selected from the above and optionally restriction enzymes, such as screening kits, are provided.
- the restriction enzyme used is KpnI.
- the restriction enzyme used is XbaI.
- the kit includes the kit.
- the restriction enzyme used is AflII.
- the present invention further follows the sequence selected from SEQ ID NOs: 86 to 109, 150 located at the 3'end and the 28th to 5'sides of SEQ ID NO: 6 optionally added to the 5'end of the sequence.
- a forward primer containing any contiguous sequence (eg, a contiguous sequence of any length) and any contiguous sequence of 20 or more bases located 3'from position 50 of SEQ ID NO: 6.
- a kit containing a primer set comprising a reverse primer containing the sequence (eg, SEQ ID NOs: 65, 110), eg, the primer set shown in Table 6 above, and a corresponding limiting enzyme, eg, a screening kit. provide.
- the restriction enzyme comprises KpnI. If the primer set contains a forward primer that has or contains any contiguous 15 or more bases sequence in SEQ ID NO: 50, the restriction enzyme comprises XbaI. If the primer set contains a forward primer that has or contains any contiguous 15 or more bases sequence in SEQ ID NO: 55, the restriction enzyme comprises AflII.
- the present invention is also a primer set capable of amplifying a region having a base sequence selected from the group consisting of SEQ ID NOs: 160 to 168, 185 to 193, 1 to 6, 19 to 36, 69 to 77, 135 to 149 by PCR. And a screening kit including the probe of the present invention.
- primer sets, probes and kits can be used for detecting the genetic features of the present invention, used for the screening method of the present invention, and the like.
- these primer sets and kits include instructions including detection of genetic features of the present invention and explanations of the screening method of the present invention, such as instructions for use and media on which information about the method of use is recorded, for example.
- Flexible discs, CDs, DVDs, Blu-ray discs, memory cards, USB memory sticks and the like may be included.
- a method for producing a plant-derived extract and a product using the extract is obtained from the plant of the present invention or the seeds or leaves (for example, dried leaves or fresh leaves) of the plant.
- a method for producing a stevia extract (hereinafter, may be referred to as "method for producing an extract of the present invention") including a step of obtaining the extract is provided.
- a method for producing a steviol glycoside refined product which comprises a step of purifying a steviol glycoside from the extract obtained by the method for producing an extract of the present invention (hereinafter, "the steviol glycoside refined product of the present invention”). (Sometimes referred to as "manufacturing method”) is provided.
- a method for producing a refined steviol glycoside product comprises a step of purifying a steviol glycoside from the obtained extract.
- the extract containing the steviol glycoside can be obtained by reacting the fresh or dried leaves of the plant of the present invention with an appropriate solvent (an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone). It can.
- an appropriate solvent an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone.
- an appropriate solvent such as water or an organic solvent such as alcohol, ether and acetone.
- an appropriate solvent an aqueous solvent such as water or an organic solvent such as alcohol, ether and acetone.
- extracts containing steviol glycosides are mixed with ethyl acetate and other organic solvents: water gradient, high performance liquid chromatography (HPLC), gas chromatography, time-of-flight.
- Individual steviol glycosides can be purified by using known methods such as mass spectrometry (TOF-MS) and ultra (High) Performance Liquid Chromatography (UPLC).
- steviol glycosides examples include RebA, RebB, RebC, RebD, RebE, RebF, RebI, RebJ, RebK, RebM, RebNRebO, RebQ, RebR, Zulcoside A, Rubusoside, Steviolmonoside, Steviolbioside, Stevioside and the like. Be done.
- the steviol glycoside comprises RebA, RebB, RebC, RebD, RebE, RebF, RebM, RebN, RebO, stevioside, steviolbioside, rubusoside, zulucoside A or a combination thereof.
- the steviol glycoside comprises RebD, RevM, or a combination thereof.
- the extract obtained by the method for producing the extract of the present invention contains RebD, RevM or both in a higher content as compared with the wild-type Stevia species.
- the extract of the present invention contains 300% or more, 400% or more, 500% or more, 600% or more, 700% or more, 800% or more of RebD, RebM or both as compared with the extract obtained from the wild-type Stevia species.
- the present invention is a step of mixing the steviol glycoside refined product obtained by the extract of the present invention and / or the method for producing the steviol glycoside refined product of the present invention with other components.
- the present invention provides pharmaceuticals, flavors or foods and drinks containing steviol glycosides obtained by the above-mentioned production method.
- food and drink means beverages and foods. Therefore, in certain embodiments, the present invention provides pharmaceuticals, flavors, beverages or foods, and also provides methods for producing such pharmaceuticals, flavors, beverages or foods.
- the present invention provides a nucleotide sequence of the Stevia plant of the present invention.
- the nucleotide sequence of a Stevia plant having the genetic feature X-1 contains or consists of a nucleotide sequence selected from SEQ ID NOs: 160-162, 202.
- the nucleotide sequence of a Stevia plant having the genetic feature X-2 comprises or consists of a nucleotide sequence selected from SEQ ID NOs: 163 to 165, 203.
- the nucleotide sequence of a Stevia plant having the genetic feature X-3 comprises or consists of a nucleotide sequence selected from SEQ ID NOs: 166 to 168, 204.
- the nucleotide sequence of a Stevia plant having genetic feature A comprises or consists of a nucleotide sequence selected from SEQ ID NOs: 19-21, 69.
- the nucleotide sequence of a Stevia plant having the genetic feature B-1 contains or consists of a nucleotide sequence selected from SEQ ID NOs: 22 to 24 and 70.
- the nucleotide sequence of a Stevia plant having the genetic feature B-2 contains or consists of a nucleotide sequence selected from SEQ ID NOs: 25 to 27, 71.
- the nucleotide sequence of a Stevia plant having the genetic feature B-3 contains or consists of a nucleotide sequence selected from SEQ ID NOs: 28-30 and 72.
- the nucleotide sequence of a Stevia plant having the genetic feature B-4 comprises or consists of a nucleotide sequence selected from SEQ ID NOs: 31-33, 62, 73.
- the nucleotide sequence of a Stevia plant having the genetic characteristics C or D comprises or consists of a nucleotide sequence selected from SEQ ID NOs: 34-36, 74.
- Example 1 Verification of the relationship between RevM content and genetic feature B (1) Based on commercially available Stevia seeds, individuals are selected based on growth conditions, leaf morphology, total steviol glycoside (TSG), RebA, RebD, and RevM contents, etc., and two isolated populations, I and II populations. Got Verification was performed using 62 individuals from the I population and 109 individuals from the II population. Each individual was divided into 3 groups of 0.2% or more, 0.1% or more to less than 0.2%, and 0% or more to less than 0.1% based on the RevM content, and the presence or absence of genetic feature B-1 was observed. investigated.
- TSG total steviol glycoside
- RebA RebA
- RebD RevM contents
- PCR was carried out using the following primers, a restriction enzyme (KpnI) was added to the PCR product, an enzymatic reaction was carried out at 37 ° C., and a treatment with the restriction enzyme was carried out. After the restriction enzyme treatment, electrophoresis was performed with a microchip-type electrophoresis device LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the primer sequence is as follows.
- Fw primer 5'-TAATCATCCAAACCCTAATCTCGCCAAACAAACCGGGTAC-3'(SEQ ID NO: 45)
- Rv primer 5'-GAGAGACATTGGCAACTC-3'(SEQ ID NO: 46)
- the obtained PCR product (about 297 bp in length) was treated with a KpnI restriction enzyme, and those that did not produce a restriction enzyme-treated product of about 260 bp (for example, SEQ ID NO: 49) were regarded as B-1 positive.
- SEQ ID NO: 49 for example, SEQ ID NO: 49
- the group containing 0.2% or more was preferentially detected by this genetic feature, and it was proved that the frequency of occurrence of positive individuals was statistically significantly different between the groups (by chi-square test).
- the goodness-of-fit test and null hypothesis assume that the marker test results and phenotypes are not linked and the frequency distribution is even. See the table below for the test results).
- Example 2 Verification of the relationship between RevM content and genetic feature B (2)
- individuals with a RevM ratio of 2% or more could be selected even in isolated populations other than the verification population as shown in the table below, which is a practical selection. It was confirmed that it could be a marker.
- the selection results of high RevM plants are shown in the table below. " ⁇ " in the table indicates that the test result of genetic feature B is positive.
- the genetic feature B-1 was detected in the same manner as in Example 1, and the genetic features B-2 to B-4 were detected as follows.
- PCR was performed using the following primers, a restriction enzyme (XbaI) was added to the PCR product, an enzymatic reaction was performed at 37 ° C., and treatment with the restriction enzyme was performed. After the restriction enzyme treatment, electrophoresis was performed with a microchip-type electrophoresis device LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- XbaI restriction enzyme
- electrophoresis was performed with a microchip-type electrophoresis device LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- Fw primer 5'-AAGGTTCTTTATTTTTAAACTTATTGTTAATTTTATTGTATTTAG-3'(SEQ ID NO: 50)
- Rv primer 5'-CCTTAGTACACATGCTACAC-3'(SEQ ID NO: 51)
- the obtained PCR product (about 383 bp in length) was treated with an XbaI restriction enzyme, and those that did not produce a restriction enzyme-treated product of about 344 bp (for example, SEQ ID NO: 54) were regarded as B-2 positive.
- PCR was performed using the following primers, a restriction enzyme (AflII) was added to the PCR product, an enzymatic reaction was performed at 37 ° C., and treatment with the restriction enzyme was performed. After the restriction enzyme treatment, electrophoresis was performed with a microchip-type electrophoresis device LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the primer sequence is as follows.
- Fw primer 5'-CGATGGTTTTTGCTACATGAAAACCTAGAAGACGAAAACCCGCTTAA-3'(SEQ ID NO: 55)
- Rv primer 5'-ACCAGCAATAATCCTTGAATTGA3'(SEQ ID NO: 56)
- the obtained PCR product (about 390 bp in length) was treated with an AflII restriction enzyme, and those that did not produce a restriction enzyme-treated product of about 347 bp (for example, SEQ ID NO: 59) were regarded as B-3 positive.
- PCR was performed using the following primers to detect genetic feature B-4.
- the PCR product was electrophoresed on a microchip-type electrophoresis device LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the primer sequence is as follows. Fw primer: 5'-CGCAAAACCGTATATAC-3'(SEQ ID NO: 60)
- Those producing only about 140 bp of PCR product (eg, SEQ ID NO: 62) were considered B-4 positive.
- Example 3 Verification of association between high TSG Stevia plants and genetic feature C (1) Isolation of individuals with high sweetness component (M0 generation) Approximately 2000 wild-type stevia seeds (commercially available, introduced in August 2014) (weight equivalent) are divided into three, and 0.1%, 0.2% or 0.3% ethylenemethane is used for each. Genetic modification was performed by treating with sulfonic acid (EMS). The EMS-treated seeds and untreated seeds were sown in a greenhouse in the Suntory Research Center to obtain EMS-treated current generation (M0 generation) seedlings. No difference in germination rate was observed between the treatment concentrations.
- EMS sulfonic acid
- LC / MS-MS analysis was performed on this extract in LCMS8050 ion mode (Shimadzu LCMS8050) to quantify the concentrations of RebA, RebB, RebC, RebD, RebF, RebM, RebN and RebO, and the total was the concentration of the sweetening component. And said.
- An individual having a sweetness component concentration of about 20% was designated as a parent individual 1 (P1).
- P2 an individual derived from another Stevia plant population having a sweetness component concentration of 5% in the dried leaves was selected.
- which of the 306 mutations has sufficient genomic information (sequence coverage is x5 or more), is not continuous, and has no sequence insertions or deletions? It was examined whether it exists in the individual. As a result, it was clarified that the mutation from C to A (C49A) at position 49 of SEQ ID NO: 1 is present in the individual having a high content of the sweetness component but not in the individual having a low content of the sweetness component.
- Example 4 Verification of the relationship between high RevD Stevia plants and genetic features A to C 1. Preparation of test line A male strain (P1) having a high TSG-containing genetic characteristic and a female strain (P2) having a high RebM-containing genetic characteristic were crossed to produce a F1 hybrid (S1 generation) seed. Was sown and sown in the greenhouse in the Suntory Research Center to obtain S1 generation seedlings.
- the genetic characteristics of the high RevM-containing form have at least one of the following characteristics: B-1: Homozygous for alleles where the base at the position corresponding to position 40 of SEQ ID NO: 2 is T.
- B-2 Homozygous for alleles whose base is T at the position corresponding to position 44 of SEQ ID NO: 3.
- B-3 Homozygous for alleles whose base is C at the position corresponding to position 48 of SEQ ID NO: 4.
- B-4 Homozygous for alleles lacking the portion corresponding to positions 55-72 of SEQ ID NO: 5.
- these genetic features relate to high RevM content characteristics.
- the genetic characteristics of the high TSG-containing type have the following characteristics.
- C Heterozygous for alleles whose base is A at the position corresponding to position 49 of SEQ ID NO: 6.
- the above genetic characteristics relate to high TSG-containing characteristics.
- P1 and P2 are both progeny of individuals whose genes have been modified by ethyl methanesulfonic acid (EMS) treatment.
- EMS ethyl methanesulfonic acid
- Genomic DNA was extracted from the fresh leaves of each individual tested in Example 4 and the possession status of genetic characteristics B-1 and C was investigated. ..
- PCR was carried out using the following primers, a restriction enzyme (KpnI) was added to the PCR product, an enzymatic reaction was carried out at 37 ° C., and treatment with the restriction enzyme was carried out. After the restriction enzyme treatment, electrophoresis was performed with a microchip-type electrophoresis device LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- KpnI restriction enzyme
- electrophoresis was performed with a microchip-type electrophoresis device LabChip GX Touch HT, and markers were identified by the band pattern after electrophoresis.
- the primer sequence is as follows.
- Fw primer 5'-TAATCATCCAAACCCTAATCTCGCCAAACAAACCGGGTAC-3'(SEQ ID NO: 45)
- Rv primer 5'-GAGAGACATTGGCAACTC-3'(SEQ ID NO: 46)
- the obtained PCR product (about 297 bp in length) was treated with a KpnI restriction enzyme, and those that did not produce a restriction enzyme-treated product of about 260 bp (for example, SEQ ID NO: 49) were regarded as genetic feature B-1 positive.
- PCR was carried out using the following primers, a restriction enzyme (SpeI) was added to the PCR product, and an enzymatic reaction was carried out at 37 ° C. After the restriction enzyme treatment, electrophoresis was performed with a microchip-type electrophoresis apparatus LabChip GX Touch HT (PerkinElmer), and markers were identified by the band pattern after electrophoresis.
- SpeI restriction enzyme
- LabChip GX Touch HT LabChip GX Touch HT
- the present invention makes it possible to provide a stevia plant having a high yield of leaves and steviol glycosides, so that the production of steviol glycosides can be made more efficient. Further, according to the present invention, individuals having a low pollen-forming ability can be selected before pollen is formed, so that breeding efficiency can be improved.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Public Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
Abstract
Description
[1]
野生型に比べ花粉形成能が低いステビア植物体。
[2]
配列番号151の79位に相当する位置の塩基がCであるアレルについてヘテロ又はホモ接合性である、配列番号152の65位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、及び/又は、配列番号153の24位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、[1]に記載の植物体。
[3]
以下の(1)~(7)の遺伝的特徴の少なくとも1つをさらに有する、[1]又は[2]に記載の植物体。
(1)配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号1の201位に相当する位置の塩基がAであるアレルについてホモ接合性である。
(6)配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性である。
(7)配列番号6の49位に相当する位置の塩基がAであるアレルについてホモ接合性である。
以下の(1)~(2)の特徴の少なくとも1つを有する[3]に記載の植物体。
(1)乾燥葉の単位質量当たり3%以上のRebDを含む。
(2)乾燥葉の単位質量当たり0.2%以上のRebMを含む。
[5]
非遺伝子組換植物体である、[1]~[4]のいずれか一項に記載の植物体。
[6]
突然変異誘発処理を行ったステビア植物体及びその子孫植物体を含む、[1]~[5]のいずれか一項に記載の植物体。
[7]
[1]~[6]のいずれか一項に記載の植物体の種子、組織、組織培養物又は細胞。
[8]
胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルスから選択される、[7]に記載の組織、組織培養物又は細胞。
[9]
[1]~[6]のいずれか一項に記載の植物体と第2のステビア植物体とを交雑させる工程を含む、花粉形成能が低いステビア植物体を作出する方法。
[10]
第2の植物体が[1]~[6]のいずれか一項に記載の植物体である、[9]に記載の方法。
[1]~[6]のいずれか一項に記載の植物体、[7]又は[8]に記載の種子、組織、組織培養物又は細胞の抽出物。
[12]
[1]~[6]のいずれか一項に記載の植物体、[7]又は[8]に記載の種子、組織、組織培養物又は細胞から抽出物を得る工程を含む、ステビア抽出物の製造方法。
[13]
[1]~[6]のいずれか一項に記載の植物体、[7]又は[8]に記載の種子、組織、組織培養物又は細胞から抽出物を得る工程と、得られた抽出物からステビオール配糖体を精製する工程とを含む、ステビオール配糖体精製品の製造方法。
[14]
ステビオール配糖体が、レバウジオシドA、レバウジオシドB、レバウジオシドC、レバウジオシドD、レバウジオシドE、レバウジオシドF、レバウジオシドM、レバウジオシドN、レバウジオシドO、ステビオシド、ステビオールビオシド、ルブソシド、ズルコシドA又はこれらの組合せを含む、[13]に記載の方法。
[15]
[11]に記載の抽出物又はその精製品を提供する工程、及び
前記抽出物又は精製品を、飲食品、甘味組成物、香料又は医薬品の原料に添加する工程
を含む、飲食品、甘味組成物、香料又は医薬品の製造方法。
被験ステビア植物体のゲノムから、配列番号151の79位に相当する位置の塩基がCであるアレルについてヘテロ又はホモ接合性である、配列番号152の65位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、及び/又は、配列番号153の24位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、という遺伝的特徴の存在及び/又は不在を検出する工程を含む、低花粉形成能ステビア植物体をスクリーニングする方法。
[17]
被験ステビア植物体のゲノムから以下の(1)~(7)の遺伝的特徴の存在及び/又は不在を検出する工程をさらに含む、[16]に記載の方法。
(1)配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号1の201位に相当する位置の塩基がAであるアレルについてホモ接合性である。
(6)被験ステビア植物体のゲノムから、配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性である。
(7)被験ステビア植物体のゲノムから、配列番号6の49位に相当する位置の塩基がAであるアレルについてホモ接合性である。
[18]
遺伝的特徴を検出する工程が、CAPS法、dCAPS法又はTaqMan PCR法を用いて行われる、[16]又は[17]に記載の方法。
[19]
被験ステビア植物組織の花粉形成能を評価する工程をさらに含む、[16]~[18]のいずれか一項に記載の方法。
配列番号151の79位に相当する位置の塩基がCであるアレルについてヘテロ又はホモ接合性である、配列番号152の65位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、及び/又は、配列番号153の24位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、という遺伝的特徴の存在及び/又は不在を検出するための試薬を含む、低花粉形成能ステビア植物体のスクリーニングキット。
[21]
以下の(1)~(7)の遺伝的特徴の存在及び/又は不在を検出するための試薬をさらに含む、[20]に記載のキット。
(1)配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号1の201位に相当する位置の塩基がAであるアレルについてホモ接合性である。
(6)配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性である。
(7)配列番号6の49位に相当する位置の塩基がAであるアレルについてホモ接合性である。
[22]
試薬が、CAPS法、dCAPS法又はTaqMan PCR法に使用するプライマー及び/又はプローブを含む、[20]又は[21]に記載のキット。
[23]
配列番号151の79位に相当する位置にTからCへの変異を導入する工程、及び/又は、配列番号152の65位に相当する位置にAからTへの変異を導入する工程、及び/又は、配列番号153の24位に相当する位置にAからTへの変異を導入する工程を含む、低花粉形成能ステビア植物体を作出する方法。
[24]
変異の導入が、突然変異誘発処理によって行われる、[23]に記載の方法。
なお、本明細書において引用した全ての文献、及び公開公報、特許公報その他の特許文献は、参照として本明細書に組み込むものとする。また、本明細書は、2019年4月11日に出願された本願優先権主張の基礎となる日本国特許出願(特願2019-075611号)の明細書及び図面に記載の内容を包含する。
本発明は、野生型に比べ花粉形成能が低いステビア植物体(以下、「本発明の植物体」又は「本発明のステビア植物体」と総称する場合がある)を提供する。
ステビアは、ステビア・レバウディアナ・ベルトニー(Stevia Rebaudiana Bertoni)の学名を有する植物である。
別の態様において、本発明のステビア植物体は、以下の(B-1)~(B-4)の少なくとも1つの遺伝的特徴(以下、「本発明の遺伝的特徴B」と称する場合がある)を有する。
(B-1)配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性である(以下、「本発明の遺伝的特徴B-1」と称する場合がある)。
(B-2)配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性である(以下、「本発明の遺伝的特徴B-2」と称する場合がある)。
(B-3)配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性である(以下、「本発明の遺伝的特徴B-3」と称する場合がある)。
(B-4)配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性である(以下、「本発明の遺伝的特徴B-4」と称する場合がある)。
別の態様において、本発明のステビア植物体は、配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性であるという遺伝的特徴(以下、「本発明の遺伝的特徴C」と称する場合がある)を有する。
別の態様において、本発明のステビア植物体は、配列番号6の49位に相当する位置の塩基がAであるアレルについてホモ接合性であるという遺伝的特徴(以下、「本発明の遺伝的特徴D」と称する場合がある)を有する。
ここでは簡潔のため本発明の遺伝的特徴Aを例に説明したが、本発明の遺伝的特徴X(遺伝的特徴X-1~X-3を含む)、B(遺伝的特徴B-1~B-4を含む)、C及びDについても同様である。
特定の態様において、「配列番号152に相当する塩基配列からなる部分」には、例えば、配列番号156の塩基配列を含むフォワードプライマーと、配列番号157の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号153に相当する塩基配列からなる部分」には、例えば、配列番号158の塩基配列を含むフォワードプライマーと、配列番号159の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号2に相当する塩基配列からなる部分」には、例えば、配列番号9の塩基配列を含むフォワードプライマーと、配列番号10の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号3に相当する塩基配列からなる部分」には、例えば、配列番号11の塩基配列を含むフォワードプライマーと、配列番号12の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号4に相当する塩基配列からなる部分」には、例えば、配列番号13の塩基配列を含むフォワードプライマーと、配列番号14の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号5に相当する塩基配列からなる部分」には、例えば、配列番号15の塩基配列を含むフォワードプライマーと、配列番号16の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号6に相当する塩基配列からなる部分」には、例えば、配列番号17の塩基配列を含むフォワードプライマーと、配列番号18の塩基配列を含むリバースプライマーとを用いたPCRにより増幅され得るステビア植物のゲノムの部分が含まれる。
特定の態様において、「配列番号152の65位に相当する位置の塩基がTであるアレル」は、配列番号163、164又は165の塩基配列を含む。
特定の態様において、「配列番号153の24位に相当する位置の塩基がTであるアレル」は、配列番号166、167又は168の塩基配列を含む。
特定の態様において、「配列番号1の201位に相当する位置の塩基がAであるアレル」は、配列番号19、20又は21の塩基配列を含む。
特定の態様において、「配列番号2の40位に相当する位置の塩基がTであるアレル」は、配列番号22、23又は24の塩基配列を含む。
特定の態様において、「配列番号3の44位に相当する位置の塩基がTであるアレル」は、配列番号25、26又は27の塩基配列を含む。
特定の態様において、「配列番号4の48位に相当する位置の塩基がCであるアレル」は、配列番号28、29又は30の塩基配列を含む。
特定の態様において、「配列番号5の55~72位に相当する部分が欠失しているアレル」は、配列番号31、32又は33の塩基配列を含む。
特定の態様において、「配列番号6の49位に相当する位置の塩基がAであるアレル」は、配列番号34、35又は36の塩基配列を含む。
また、(X-1)配列番号151の79位に相当する位置におけるTからCへの変異、(X-2)配列番号152の65位に相当する位置におけるAからTへの変異、(X-3)配列番号153の24位に相当する位置におけるAからTへの変異、(A)配列番号1の201位に相当する位置におけるCからAへの変異、(B-1)配列番号2の40位に相当する位置におけるAからTへの変異、(B-2)配列番号3の44位に相当する位置におけるCからTへの変異、(B-3)配列番号4の48位に相当する位置におけるGからCへの変異、(B-4)配列番号5の55~72位に相当する部分の欠失、及び(C)配列番号6の49位に相当する位置におけるCからAへの変異からなる群から選択される変異を、「本発明の多型」又は「本発明の変異」と総称することがある。
候補植物体が遺伝的特徴X-1を有する場合、例えば、候補植物体のゲノムDNAに対し、配列番号169に示す塩基配列を有するフォワードプライマー及び配列番号170に示す塩基配列を有するリバースプライマーを用いてPCR増幅を行い、得られたPCR産物(約166bp長、例えば、配列番号171)に対し制限酵素AluIによる処理を行うと、約120bp長(例えば、配列番号172)及び約46bp長(例えば、配列番号173)のバンドが生じる。一方、PCR増幅により、例えば、配列番号174のPCR産物(約166bp長)が得られ、これに対しAluI制限酵素処理を行っても約166bp長のバンド(例えば、配列番号174)しか得られない場合、その候補植物体は遺伝的特徴X-1を有しない。
上記bp長に関し、「約」とは、±5bpを意味する。制限酵素処理は、使用する各制限酵素の販売元が推奨する条件に従って行うことができる。
(1)被験ステビア植物体を開花させる。
(2)開花した花に含まれる花粉の数をカウントする。
被験ステビア植物体は単独で栽培してもよいし、野生型ステビア植物体(対照)と同一環境下で一緒に栽培してもよい。単独で栽培する場合は、上記評価手法に、被験ステビア植物体に形成された花粉の数と、同様の条件下で栽培された野生型ステビア植物体に形成される花粉の数(例えば、文献や別個の実験で得られたデータに基づくもの)とを比較する工程が含まれてもよい。野生型ステビア植物体と一緒に栽培する場合、上記評価手法に、被験ステビア植物体に形成された花粉の数と、一緒に栽培した野生型ステビア植物体に形成された花粉の数とを比較する工程が含まれてもよい。
開花は短日条件下で誘導することができる。短日条件は、暗期が10時間超、好ましくは11時間以上である。具体的な暗期の長さは、例えば、11時間、12時間、13時間、14時間、15時間、16時間、17時間、18時間などであってよい。
特定の態様において、花粉のカウントは花が十分開花した状態で行う。
ここで乾燥葉とは、本発明のステビア植物体の新鮮葉を乾燥させることにより含水量を3~4重量%にまで減らしたものをいう。
さらに、このようにして得られた抽出液に対し、酢酸エチルその他の有機溶媒:水の勾配、高速液体クロマトグラフィー(High Performance Liquid Chromatography:HPLC)、ガスクロマトグラフィー、飛行時間型質量分析(Time-of-Flight mass spectrometry:TOF-MS)、超高性能液体クロマトグラフィー(Ultra (High) Performance Liquid chromatography:UPLC)等の公知の方法を用いることによりRebDを精製することができる。
本発明は、別の実施態様において、本発明のステビア植物体と第2のステビア植物体とを交雑させる工程を含む、野生型より花粉形成能が低いステビア植物体を作出する方法(以下、「本発明の作出方法」と称する場合がある)を提供する。
当該方法により作出される「野生型より花粉形成能が低いステビア植物体」は、本発明の植物体と同じ表現型と遺伝的性質を有する。
本発明の作出方法によって得られる植物体における花粉形成能、RebD及びRebM含量の範囲等は、本発明の植物体について上記したとおりである。
一般に、植物細胞は、培養の間に変異を伴うことがあるため、より安定した形質維持のために植物個体に戻すことが好ましい。
本発明の植物体を宿主として事後的に遺伝子組み換え(例えばゲノム編集等により)を行って得られた植物体(例えば、本発明の植物体を宿主として遺伝子組み換えを行って、さらに別の形質を付加した植物体)も、本発明の範囲から除外されるものではない。
本発明の植物体及び本発明の植物体と同じ表現型と遺伝的性質を有する植物体は、当該植物体の組織から本発明の遺伝的特徴を検出することによりスクリーニングすることができる。ここで、「スクリーニング」とは、本発明の植物体とそれ以外の植物体とを識別し、本発明の植物体を選択することを意味する。
したがって、本発明は、別の側面において、被験植物のゲノムから本発明の遺伝的特徴X、A、B、C及びDの少なくとも1つの存在及び/又は不在を検出する工程を含む、花粉形成能の低いステビア植物体をスクリーニングする方法(以下、「本発明のスクリーニング方法」と称する場合がある)を提供する。
本発明のスクリーニング方法は、上記の少なくとも1つの遺伝的特徴の存在が検出された植物体を被験植物の中から選択する工程をさらに含んでもよい。
(X-1)配列番号151の79位に相当する位置の塩基がCであるアレル(例えば、配列番号160、161又は162の塩基配列を含むアレル)、
(X-2)配列番号152の65位に相当する位置の塩基がTであるアレル(例えば、配列番号163、164又は165の塩基配列を含むアレル)、
(X-3)配列番号153の24位に相当する位置の塩基がTであるアレル(例えば、配列番号166、167又は168の塩基配列を含むアレル)、
(A)配列番号1の201位に相当する位置の塩基がAであるアレル(例えば、配列番号69の塩基配列を含むアレル)、
(B-1)配列番号2の40位に相当する位置の塩基がTであるアレル(例えば、配列番号70の塩基配列を含むアレル)、
(B-2)配列番号3の44位に相当する位置の塩基がTであるアレル(例えば、配列番号71の塩基配列を含むアレル)、
(B-3)配列番号4の48位に相当する位置の塩基がCであるアレル(例えば、配列番号72の塩基配列を含むアレル)、
(B-4)配列番号5の55~72位に相当する部分が欠失しているアレル(例えば、配列番号73の塩基配列を含むアレル)、及び
(C)配列番号6の49位に相当する位置の塩基がAであるアレル(例えば、配列番号74の塩基配列を含むアレル)
からなる群から選択されるアレルの存在の検出、及び/又は、
(x-1)配列番号151の79位に相当する位置の塩基がTであるアレル(例えば、配列番号185、186又は187の塩基配列を含むアレル)、
(x-2)配列番号152の65位に相当する位置の塩基がAであるアレル(例えば、配列番号188、189又は190の塩基配列を含むアレル)、
(x-3)配列番号153の24位に相当する位置の塩基がAであるアレル(例えば、配列番号191、192又は193の塩基配列を含むアレル)、
(a)配列番号1の201位に相当する位置の塩基がTであるアレル(例えば、配列番号1の塩基配列を含むアレル)、
(b-1)配列番号2の44位に相当する位置の塩基がAであるアレル(例えば、配列番号2の塩基配列を含むアレル)、
(b-2)配列番号3の40位に相当する位置の塩基がCであるアレル(例えば、配列番号3の塩基配列を含むアレル)、
(b-3)配列番号4の48位に相当する位置の塩基がGであるアレル(例えば、配列番号4の塩基配列を含むアレル)、
(b-4)配列番号5の55~72位に相当する部分が欠失していないアレル(例えば、配列番号5の塩基配列を含むアレル)、及び
(c)配列番号6の49位に相当する位置の塩基がCであるアレル(例えば、配列番号6の塩基配列を含むアレル)
からなる群から選択されるアレルの不在の検出
により決定することができる。
(X-1)配列番号151の79位に相当する位置の塩基がCであるアレル(例えば、配列番号160、161又は162の塩基配列を含むアレル)、
(X-2)配列番号152の65位に相当する位置の塩基がTであるアレル(例えば、配列番号163、164又は165の塩基配列を含むアレル)、
(X-3)配列番号153の24位に相当する位置の塩基がTであるアレル(例えば、配列番号166、167又は168の塩基配列を含むアレル)、
(A)配列番号1の201位に相当する位置の塩基がAであるアレル(例えば、配列番号69の塩基配列を含むアレル)、
(B-1)配列番号2の40位に相当する位置の塩基がTであるアレル(例えば、配列番号70の塩基配列を含むアレル)、
(B-2)配列番号3の44位に相当する位置の塩基がTであるアレル(例えば、配列番号71の塩基配列を含むアレル)、
(B-3)配列番号4の48位に相当する位置の塩基がCであるアレル(例えば、配列番号72の塩基配列を含むアレル)、
(B-4)配列番号5の55~72位に相当する部分が欠失しているアレル(例えば、配列番号73の塩基配列を含むアレル)、及び
(C)配列番号6の49位に相当する位置の塩基がAであるアレル(例えば、配列番号74の塩基配列を含むアレル)
からなる群から選択されるアレルの不在の検出、及び/又は、
(x-1)配列番号151の79位に相当する位置の塩基がTであるアレル(例えば、配列番号185、186又は187の塩基配列を含むアレル)、
(x-2)配列番号152の65位に相当する位置の塩基がAであるアレル(例えば、配列番号188、189又は190の塩基配列を含むアレル)、
(x-3)配列番号153の24位に相当する位置の塩基がAであるアレル(例えば、配列番号191、192又は193の塩基配列を含むアレル)、
(a)配列番号1の201位に相当する位置の塩基がTであるアレル(例えば、配列番号1の塩基配列を含むアレル)、
(b-1)配列番号2の44位に相当する位置の塩基がAであるアレル(例えば、配列番号2の塩基配列を含むアレル)、
(b-2)配列番号3の40位に相当する位置の塩基がCであるアレル(例えば、配列番号3の塩基配列を含むアレル)、
(b-3)配列番号4の48位に相当する位置の塩基がGであるアレル(例えば、配列番号4の塩基配列を含むアレル)、
(b-4)配列番号5の55~72位に相当する部分が欠失していないアレル(例えば、配列番号5の塩基配列を含むアレル)、及び
(c)配列番号6の49位に相当する位置の塩基がCであるアレル(例えば、配列番号6の塩基配列を含むアレル)
からなる群から選択されるアレルの存在の検出
により決定することができる。
あるいは、本発明の多型とプライマー配列とは重複させず、かつ本発明の遺伝子変異をPCR増幅させることが可能なようにプライマー配列を設計し、増幅されたヌクレオチド断片の塩基配列をシーケンスすることにより、本発明の遺伝的特徴を検出することができる。
PCR及びアガロースゲル電気泳動については、以下を参照:Sambrook, Fritsch and Maniatis, ”Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press。
シークエンス法とは、変異を含む領域をPCRにて増幅させ、Dye Terminatorなどを用いてDNA配列をシークエンスすることで、変異の有無を解析する方法である(上記Sambrook, Fritsch and Maniatis)。
DNAマイクロアレイは、ヌクレオチドプローブの一端が支持体上にアレイ状に固定されたものであり、DNAチップ、Geneチップ、マイクロチップ、ビーズアレイ等を包含する。本発明の多型と相補的な配列を含むプローブを用いることで、網羅的に本発明の多型の有無を検出することができる。DNAチップなどのDNAマイクロアレイアッセイとしてはGeneChipアッセイが挙げられる(Affymetrix社;米国特許第6,045,996号、同第5,925,525号、及び同第5,858,659号参照)。GeneChip技術は、チップに貼り付けたオリゴヌクレオチドプローブの小型化高密度マイクロアレイを利用するものである。
TILLING(Targeting Induced Local Lesions IN Genomes)法とは、変異導入した突然変異体集団のゲノム中の変異ミスマッチをPCR増幅とCEL Iヌクレアーゼ処理によってスクリーニングする方法である。
フォワードプライマー:ACGGTTTACATCTCTCAGTCATCTC(配列番号169)
リバースプライマー:GCCACGTCATTATAATCATCCACAA(配列番号170)
フォワードプライマー:ACGGTTTACATCTCTCAGTCATCTC(配列番号169)
リバースプライマー:GTCGAGCTTACAAAACCATTTACCA(配列番号175)
・プライマーセット:
配列番号181又は184の257位より5’側に位置する任意の連続する15塩基以上の配列(例えば、配列番号169)を含むフォワードプライマーと、配列番号180、194~201から選択される配列の3’末端から15~29塩基長の連続する配列を含むリバースプライマーとを含む、プライマーセット。プライマーの配列は、上記の条件を満たす範囲で最適化することができる。プライマー設計の最適化については、例えば、上記Sambrook and Russell, ”Molecular Cloning: A Laboratory Manual” 3rd Edition (2001), Cold Spring Harbor Laboratory Press等を参照のこと。また、上記各プライマーは、15~50塩基長、18~48塩基長、20~45塩基長、30~65塩基長等であってよい。
フォワードプライマー:ATGGTTTGGGAATAGCTCTGTTGTT(配列番号37)
リバースプライマー:AGAACTTTGTTCTTGAACCTCTTG(配列番号38)
(B-1)配列番号45に示す塩基配列を含むフォワードプライマー及び配列番号46に示す塩基配列を含むリバースプライマーを含む、プライマーセット、
(B-2)配列番号50に示す塩基配列を含むフォワードプライマー及び配列番号51に示す塩基配列を含むリバースプライマーを含む、プライマーセット、
(B-3)配列番号55に示す塩基配列を含むフォワードプライマー及び配列番号56に示す塩基配列を含むリバースプライマーを含む、プライマーセット、又は
(B-4)配列番号60に示す塩基配列を含むフォワードプライマー及び配列番号61に示す塩基配列を含むリバースプライマーを含む、プライマーセット。
(B-1’’)配列番号45における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号46における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(B-2’’)配列番号50における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号51における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、
(B-3’’)配列番号55における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号56における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット、あるいは(B-4’’)配列番号60における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマー及び配列番号61における任意の連続する15塩基以上の配列を有する又は含むリバースプライマーを含む、プライマーセット。
このようなプライマーは、前記任意の連続する15塩基以上の配列が3‘側末端に存在すれば、15~50塩基長、20~45塩基長、30~65塩基長の長さにあってもよい。
・プライマーセット:
3’末端に位置する配列番号86~109、150から選択される配列と、任意選択で前記配列の5’末端に付加される配列番号6の28位から5’側に続く任意の連続する配列(例えば、任意の長さの連続する配列)とを含むフォワードプライマーと、配列番号6の50位より3’側に位置する任意の連続する20塩基以上の配列に相補的な配列(例えば、配列番号65、110)を含むリバースプライマーとを含む、プライマーセット。プライマーの配列は、上記の条件を満たす範囲で最適化することができる。プライマー設計の最適化については、例えば、上記Sambrook and Russell等を参照のこと。また、上記各プライマーは、15~50塩基長、18~48塩基長、20~45塩基長、30~65塩基長等であってよい。
(i)被験ステビア植物のゲノムから、本発明の遺伝的特徴(例えば、本発明の遺伝的特徴X)を検出する工程、
(ii)本発明の遺伝的特徴が検出された被験ステビア植物組織の花粉形成能を評価する工程、
(iii)本発明の遺伝的特徴が検出された被験ステビア植物体のうち、花粉形成能が低い個体を選択する工程、
(iv)選択した花粉形成能が低い個体を他のステビア植物体と交配する工程、
(v)交配により得られた子植物体のゲノムから、本発明の遺伝的特徴(例えば、本発明の遺伝的特徴X)を検出する工程、
(vi)本発明の遺伝的特徴が検出された子植物組織の花粉形成能を評価する工程、
(vii)本発明の遺伝的特徴が検出された子植物体のうち、花粉形成能が低い個体を選択する工程。
本発明のスクリーニング方法において、被験ステビア植物体は、突然変異誘発処理を行ったステビア植物及びその子孫植物を含んでもよい。突然変異誘発処理については、本発明の植物体の項に記載したとおりであり、変異誘発剤による処理や、放射線又は光線の照射による処理等を含む。
当該キットにおいて、(B-1)、(B-1’)及び(B-1’’)からなる群より選択される選択されるいずれか一つ以上のプライマーセットを用いる場合、前記キットに含まれる制限酵素はKpnIである。
当該キットにおいて、(B-2)、(B-2’)及び(B-2’’)からなる群より選択される選択されるいずれか一つ以上のプライマーセットを用いる場合、前記キットに含まれる制限酵素はXbaIである。
当該キットにおいて、(B-3)、(B-3’)及び(B-3’’)からなる群より選択される選択されるいずれか一つ以上のプライマーセットを用いる場合、前記キットに含まれる制限酵素はAflIIである。
前記プライマーセットが配列番号45における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、前記制限酵素はKpnIを含み、
前記プライマーセットが配列番号50における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、前記制限酵素はXbaIを含み、
前記プライマーセットが配列番号55における任意の連続する15塩基以上の配列を有する又は含むフォワードプライマーを含む場合は、前記制限酵素はAflIIを含む
本発明のさらなる態様において、本発明の植物体、又は当該植物体の種子若しくは葉(例えば、乾燥葉又は新鮮葉)から抽出物を得る工程を含む、ステビア抽出物の製造方法(以下、「本発明の抽出物の製造方法」と称する場合がある)が提供される。さらに、本発明の抽出物の製造方法により得られた抽出物からステビオール配糖体を精製する工程を含む、ステビオール配糖体精製品の製造方法(以下、「本発明のステビオール配糖体精製品の製造方法」と称する場合がある)が提供される。
具体的には、本発明のステビア植物体、本発明のスクリーニング方法により選別されたステビア植物体又は本発明の方法により製造されたステビア植物体からステビオール配糖体を含む抽出物を得る工程、及び、得られた抽出物からステビオール配糖体を精製する工程を含む、ステビオール配糖体精製品の製造方法が提供される。
また、ステビオール配糖体を含む抽出物を酢酸エチルその他の有機溶媒:水の勾配、高速液体クロマトグラフィー(High Performance Liquid Chromatography:HPLC)、ガスクロマトグラフィー、飛行時間型質量分析(Time-of-Flight mass spectrometry:TOF-MS)、超高性能液体クロマトグラフィー(Ultra (High) Performance Liquid chromatography:UPLC)等の公知の方法を用いることにより個々のステビオール配糖体を精製することができる。
本発明の抽出物は、野生型ステビア種から得られた抽出物と比べRebD、RebM又はその両方を300%以上、400%以上、500%以上、600%以上、700%以上、800%以上、900%以上、1100%以上、1200%以上、1300%以上、1400%以上、1500%以上、1600%以上、1700%以上、1800%以上、1900%以上、2000%以上、2100%以上、2200%以上、2300%以上、2400%以上、2500%以上、2600%以上、2700%以上、2800%以上、2900%以上、3000%以上、3100%以上、3200%以上、3300%以上、3400%以上、3500%以上、3600%以上、3700%以上、3800%以上、3900%以上、4000%以上、4100%以上、4200%以上、4300%以上、4400%以上、4500%以上、4600%以上、4700%以上、4800%以上、4900%以上、5000%以上高い含量で含んでいてもよい。ここで、本発明の抽出物と、野生型ステビア種から得られた抽出物は、同じ方法で得られたものであってよい。
本発明は、別の実施態様において、本発明のステビア植物体に係る塩基配列を提供する。
遺伝的特徴X-1を有するステビア植物体に係る塩基配列は、配列番号160~162、202から選択される塩基配列を含む、又はそれからなる。遺伝的特徴X-2を有するステビア植物体に係る塩基配列は、配列番号163~165、203から選択される塩基配列を含む、又はそれからなる。遺伝的特徴X-3を有するステビア植物体に係る塩基配列は、配列番号166~168、204から選択される塩基配列を含む、又はそれからなる。遺伝的特徴Aを有するステビア植物体に係る塩基配列は、配列番号19~21、69から選択される塩基配列を含む、又はそれからなる。遺伝的特徴B-1を有するステビア植物体に係る塩基配列は、配列番号22~24、70から選択される塩基配列を含む、又はそれからなる。遺伝的特徴B-2を有するステビア植物体に係る塩基配列は、配列番号25~27、71から選択される塩基配列を含む、又はそれからなる。遺伝的特徴B-3を有するステビア植物体に係る塩基配列は、配列番号28~30、72から選択される塩基配列を含む、又はそれからなる。遺伝的特徴B-4を有するステビア植物体に係る塩基配列は、配列番号31~33、62、73から選択される塩基配列を含む、又はそれからなる。遺伝的特徴C又はDを有するステビア植物体に係る塩基配列は、配列番号34~36、74から選択される塩基配列を含む、又はそれからなる。
市販ステビア種子をベースに、生育状況、葉形態、総ステビオール配糖体(TSG)、RebA、RebD、RebMの含量等を基準に個体選抜を行い、2つの分離集団、第I及び第II個体群を得た。第I個体群からの62個体、第II個体群からの109個体を用い、検証を行った。各個体をRebM含量に基づいて0.2%以上、0.1%以上~0.2%未満、0%以上~0.1%未満の3群に分割し、遺伝的特徴B-1の有無を調査した。具体的には、以下のプライマーを用いてPCRを行い、PCR産物に制限酵素(KpnI)を添加し、37℃で酵素反応を行い、制限酵素による処理を行った。制限酵素処理後、マイクロチップ型電気泳動装置LabChip GX Touch HTにより電気泳動を行い、電気泳動後のバンドパターンによってマーカーの識別を行った。
プライマーの配列は以下のとおり。
Fwプライマー:5’-TAATCATCCAAACCCTAATCTCGCCAAACAACCGGGTAC-3’(配列番号45)
Rvプライマー:5’-GAGGAAGACATTGGCAACTC-3’(配列番号46)
得られたPCR産物(約297bp長)に対しKpnI制限酵素処理を行い、約260bpの制限酵素処理産物(例えば、配列番号49)を生じなかったものをB-1陽性とした。その結果、0.2%以上含有群が本遺伝的特徴により優先的に検出される結果となり、陽性個体の出現頻度が群間で統計的に有意に異なることが証明された(カイ二乗検定による適合度検定、帰無仮説はマーカー検定結果と表現型が紐づかず頻度分布が均等であると仮定。検定結果は下表を参照)。
遺伝的特徴Bを用いて高RebM植物体の選抜を行ったところ、検証用集団以外の分離集団においても下表のとおりRebM比率が2%以上の個体を選抜することができ、実用的な選抜マーカーになり得ることを確認した。高RebM植物体の選抜結果を以下の表に示す。表中の「○」は遺伝的特徴Bの検定結果が陽性であることを表す。
なお、遺伝的特徴B-1は実施例1と同様に検出し、遺伝的特徴B-2~B-4は以下のようにして検出した。
プライマーの配列は以下のとおり。
Fwプライマー:5’-AAGGTTCTTTATTTTTAAACTTATGTTAATTTATTGTATCTAG-3’(配列番号50)
Rvプライマー:5’-CCTTATGTACACATGCTACAC-3’(配列番号51)
得られたPCR産物(約383bp長)に対しXbaI制限酵素処理を行い、約344bpの制限酵素処理産物(例えば、配列番号54)を生じなかったものをB-2陽性とした。
プライマーの配列は以下のとおり。
Fwプライマー:5’-CGATGGTTTTTGCTACATGAAAACCCTAGAAGACGAAACCCGCTTAA-3’(配列番号55)
Rvプライマー:5’-ACCAGCAATAATCCTTGAATTAG-3’(配列番号56)
得られたPCR産物(約390bp長)に対しAflII制限酵素処理を行い、約347bpの制限酵素処理産物(例えば、配列番号59)を生じなかったものをB-3陽性とした。
プライマーの配列は以下のとおり。
Fwプライマー:5’-CGCAAACACGTATACTAATC-3’(配列番号60)
Rvプライマー:5’-TTTAGCATGGTATGTACAAC-3’(配列番号61)
約140bpのPCR産物のみ(例えば、配列番号62)を生じたものをB-4陽性とした。
(1)甘味成分高含有個体の単離(M0世代)
野生型ステビア種子(市販品種、2014年8月に導入)約2000個(重量換算)を3つに分けて、各々に対して0.1%、0.2%又は0.3%のエチレンメタンスルホン酸(EMS)処理を行って遺伝子改変を行った。
このEMS処理済み種子及び無処理の種子を、サントリー研究センター内温室にて播種し、EMS処理当代(M0世代)苗を得た。処理濃度間での発芽率差異は見られなかった。
EMS処理当代(M0世代)及び無処理個体より適量の新鮮葉をサンプリングし、LC/MS-MS(島津LCMS8050)にて甘味成分の濃度を定量した。具体的には、0.25gの新鮮葉をフリーズドライにより乾燥し、破砕物乾物0.05gを純水中に投入した。超音波処理20分にて抽出し、遠心・濾過した後に0.33mlの抽出液を得た。この抽出液をLCMS8050イオンモード(島津LCMS8050)にてLC/MS-MS分析を行い、RebA、RebB、RebC、RebD、RebF、RebM、RebN及びRebOの濃度を定量し、その合計を甘味成分の濃度とした。甘味成分濃度が約20%の個体を親個体1(P1)とした。また、親個体2(P2)として、別のステビア植物体の集団に由来する、乾燥葉中の甘味成分濃度が5%の個体を選定した。
親個体1(P1)と親個体2(P2)との交配により処理第一代(M1世代)種子を採種し、サントリー研究センター内の温室内で播種し、M1世代苗を得た(1603個体の分離集団)。上記M1世代個体より適量の新鮮葉をサンプリングし、上記(1)と同様にLC/MS-MS(島津LCMS8050)にて甘味成分を定量した。結果を図1に示す。
甘味成分の含有量が最も高い30個体(甘味成分高含有個体)と、最も低い30個体(甘味成分低含有個体)の新鮮葉からゲノムDNAを抽出し、両個体群のいずれか一方のみに存在する変異について調査した。ゲノム解析で検出した変異のうち、ゲノム情報量が十分あり(シーケンスカバレッジが×5以上)、変異が連続しておらず、配列の挿入や欠失のない306ヵ所の変異について、各変異がどの個体に存在するかを検討した。その結果、配列番号1の49位におけるCからAへの変異(C49A)が、甘味成分高含有個体には存在するが、低含有個体には存在しないことが明らかとなった。
変異C49Aをヘテロで有するステビア植物体と、変異C49Aを有しないステビア植物体とを交配し、2つの分離集団(分離集団A(443個体)及び分離集団B(446個体))を得た。両分離集団の各個体における変異C49Aの有無と、甘味成分含有量とを調査した。変異C49Aの有無の調査にはdCAPS法を用いた。各個体からゲノムDNAを抽出し、以下のプライマーを用いてPCRを行い、PCR産物に制限酵素(SpeI)を添加し、37℃で酵素反応を行った。制限酵素処理後、マイクロチップ型電気泳動装置LabChip GX Touch HT(PerkinElmer)により電気泳動を行い、電気泳動後のバンドパターンによってマーカーの識別を行った。
フォワードプライマー:5’-TTATTTAATGATCCAATGGAGGGGGTGATTCAGGTAATAAAAGGCACT-3’(配列番号112)
リバースプライマー:5’-TGAGGGTTCTCAATTGATTTCCGATTGG-3’(配列番号65)
得られた約367bpPCR産物(例えば、配列番号66又は67)に対しSpeI制限酵素処理を行い、約321bpの制限酵素処理産物(例えば、配列番号68)を生じたものを変異C49A陽性とした。
甘味成分含有量の定量は(1)と同様に行った。
各分離集団の変異C49A陽性個体及び陰性個体における甘味成分含有量の分布を図2~3に示す。これらの結果から、変異C49A陽性個体における甘味成分含有量は、各分離集団全体の甘味成分含有量の平均値より高いことが分かる。
1.試験系統の作製
高TSG含有型の遺伝的特徴を有する雄株(P1)と、高RebM含有型の遺伝的特徴を有する雌株(P2)とを交配させ、雑種第1代(S1世代)種子を採種し、サントリー研究センター内の温室内で播種し、S1世代苗を得た。
高RebM含有型の遺伝的特徴は、以下の少なくとも1つの特徴を有する。
B-1:配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性。
B-2:配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性。
B-3:配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性。
B-4:配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性。
実施例1~2に示すとおり、これらの遺伝的特徴は高RebM含有特性に係る。
高TSG含有型の遺伝的特徴は、以下の特徴を有する。
C:配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性。
実施例3に示すとおり、上記の遺伝的特徴は高TSG含有特性に係る。
また、P1及びP2は、いずれもエチルメタンスルホン酸(EMS)処理により遺伝子が改変された個体の子孫である。
上記結果が示すとおり、P1とP2との交配により、RebD含量が乾燥葉ベースで3.3質量%を超える高RebD含有個体が得られた(S1-1~S1-3)。
実施例4で試験した各個体の新鮮葉からゲノムDNAを抽出し、遺伝的特徴B-1及びCの保有状況を調査した。
遺伝的特徴B-1の検出には、以下のプライマーを用いてPCRを行い、PCR産物に制限酵素(KpnI)を添加し、37℃で酵素反応を行い、制限酵素による処理を行った。制限酵素処理後、マイクロチップ型電気泳動装置LabChip GX Touch HTにより電気泳動を行い、電気泳動後のバンドパターンによってマーカーの識別を行った。
プライマーの配列は以下のとおり。
Fwプライマー:5’-TAATCATCCAAACCCTAATCTCGCCAAACAACCGGGTAC-3’(配列番号45)
Rvプライマー:5’-GAGGAAGACATTGGCAACTC-3’(配列番号46)
得られたPCR産物(約297bp長)に対しKpnI制限酵素処理を行い、約260bpの制限酵素処理産物(例えば、配列番号49)を生じなかったものを遺伝的特徴B-1陽性とした。
フォワードプライマー:5’-TTATTTAATGATCCAATGGAGGGGGTGATTCAGGTAATAAAAGGCACT-3’(配列番号112)
リバースプライマー:5’-TGAGGGTTCTCAATTGATTTCCGATTGG-3’(配列番号65)
得られた約367bpPCR産物(例えば、配列番号66又は67)に対しSpeI制限酵素処理を行い、約321bpの制限酵素処理産物(例えば、配列番号68)を生じたものを遺伝的特徴C陽性とした。
上記結果が示すとおり、遺伝的特徴B-1を保有する個体は、そうでない個体に比べRebM含量が高い傾向が、遺伝的特徴Cを保有する個体は、そうでない個体に比べTSG含量が高い傾向が、それぞれみられた。これは、本出願人による上記先願で示された結果を確認するものである。
A:配列番号1の201位に相当する位置の塩基がAであるアレルについてホモ接合性。
上記結果が示すとおり、高RebD含有個体(S1-1~S1-3)はいずれも遺伝的特徴A、B-1及びCを保有しており、遺伝的特徴Aを保有しない個体に比べ、RebD含量が高い傾向がみられた。
野生型ステビア植物系統2種(W201、W202)と、エチルメタンスルホン酸(EMS)での変異誘発処理により遺伝子が改変された個体の子孫である変異型ステビア植物系統1種(M201)を挿し芽後、本葉8枚が展開した植物体を8時間照明のインキュベーターに移動し、花芽を誘導した。開花5~7日後の、花を横から見たときに柱頭が視認できる、十分に開花した花から花粉を採集し、花粉数をカウントした。結果を下表に示す(各処理区5つの花の平均値)。
上記結果が示すとおり、M201の花粉形成能は野生型系統に比べ顕著に低い。この表現型に関連する遺伝的特徴を調査するため、各系統の遺伝子配列を決定し、比較した結果、M201のみに遺伝的特徴X-1~X-3が見出された。
Claims (24)
- 野生型に比べ花粉形成能が低いステビア植物体。
- 配列番号151の79位に相当する位置の塩基がCであるアレルについてヘテロ又はホモ接合性である、配列番号152の65位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、及び/又は、配列番号153の24位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、請求項1に記載の植物体。
- 以下の(1)~(7)の遺伝的特徴の少なくとも1つをさらに有する、請求項1又は2に記載の植物体。
(1)配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号1の201位に相当する位置の塩基がAであるアレルについてホモ接合性である。
(6)配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性である。
(7)配列番号6の49位に相当する位置の塩基がAであるアレルについてホモ接合性である。 - 以下の(1)~(2)の特徴の少なくとも1つを有する請求項3に記載の植物体。
(1)乾燥葉の単位質量当たり3%以上のRebDを含む。
(2)乾燥葉の単位質量当たり0.2%以上のRebMを含む。 - 非遺伝子組換植物体である、請求項1~4のいずれか一項に記載の植物体。
- 突然変異誘発処理を行ったステビア植物体及びその子孫植物体を含む、請求項1~5のいずれか一項に記載の植物体。
- 請求項1~6のいずれか一項に記載の植物体の種子、組織、組織培養物又は細胞。
- 胚、分裂組織細胞、花粉、葉、根、根端、花弁、プロトプラスト、葉の切片及びカルスから選択される、請求項7に記載の組織、組織培養物又は細胞。
- 請求項1~6のいずれか一項に記載の植物体と第2のステビア植物体とを交雑させる工程を含む、花粉形成能が低いステビア植物体を作出する方法。
- 第2の植物体が請求項1~6のいずれか一項に記載の植物体である、請求項9に記載の方法。
- 請求項1~6のいずれか一項に記載の植物体、請求項7又は8に記載の種子、組織、組織培養物又は細胞の抽出物。
- 請求項1~6のいずれか一項に記載の植物体、請求項7又は8に記載の種子、組織、組織培養物又は細胞から抽出物を得る工程を含む、ステビア抽出物の製造方法。
- 請求項1~6のいずれか一項に記載の植物体、請求項7又は8に記載の種子、組織、組織培養物又は細胞から抽出物を得る工程と、得られた抽出物からステビオール配糖体を精製する工程とを含む、ステビオール配糖体精製品の製造方法。
- ステビオール配糖体が、レバウジオシドA、レバウジオシドB、レバウジオシドC、レバウジオシドD、レバウジオシドE、レバウジオシドF、レバウジオシドM、レバウジオシドN、レバウジオシドO、ステビオシド、ステビオールビオシド、ルブソシド、ズルコシドA又はこれらの組合せを含む、請求項13に記載の方法。
- 請求項11に記載の抽出物又はその精製品を提供する工程、及び
前記抽出物又は精製品を、飲食品、甘味組成物、香料又は医薬品の原料に添加する工程
を含む、飲食品、甘味組成物、香料又は医薬品の製造方法。 - 被験ステビア植物体のゲノムから、配列番号151の79位に相当する位置の塩基がCであるアレルについてヘテロ又はホモ接合性である、配列番号152の65位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、及び/又は、配列番号153の24位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、という遺伝的特徴の存在及び/又は不在を検出する工程を含む、低花粉形成能ステビア植物体をスクリーニングする方法。
- 被験ステビア植物体のゲノムから以下の(1)~(7)の遺伝的特徴の存在及び/又は不在を検出する工程をさらに含む、請求項16に記載の方法。
(1)配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号1の201位に相当する位置の塩基がAであるアレルについてホモ接合性である。
(6)被験ステビア植物体のゲノムから、配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性である。
(7)被験ステビア植物体のゲノムから、配列番号6の49位に相当する位置の塩基がAであるアレルについてホモ接合性である。 - 遺伝的特徴を検出する工程が、CAPS法、dCAPS法又はTaqMan PCR法を用いて行われる、請求項16又は17に記載の方法。
- 被験ステビア植物組織の花粉形成能を評価する工程をさらに含む、請求項16~18のいずれか一項に記載の方法。
- 配列番号151の79位に相当する位置の塩基がCであるアレルについてヘテロ又はホモ接合性である、配列番号152の65位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、及び/又は、配列番号153の24位に相当する位置の塩基がTであるアレルについてヘテロ又はホモ接合性である、という遺伝的特徴の存在及び/又は不在を検出するための試薬を含む、低花粉形成能ステビア植物体のスクリーニングキット。
- 以下の(1)~(7)の遺伝的特徴の存在及び/又は不在を検出するための試薬をさらに含む、請求項20に記載のキット。
(1)配列番号2の40位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(2)配列番号3の44位に相当する位置の塩基がTであるアレルについてホモ接合性である。
(3)配列番号4の48位に相当する位置の塩基がCであるアレルについてホモ接合性である。
(4)配列番号5の55~72位に相当する部分が欠失しているアレルについてホモ接合性である。
(5)配列番号1の201位に相当する位置の塩基がAであるアレルについてホモ接合性である。
(6)配列番号6の49位に相当する位置の塩基がAであるアレルについてヘテロ接合性である。
(7)配列番号6の49位に相当する位置の塩基がAであるアレルについてホモ接合性である。 - 試薬が、CAPS法、dCAPS法又はTaqMan PCR法に使用するプライマー及び/又はプローブを含む、請求項20又は21に記載のキット。
- 配列番号151の79位に相当する位置にTからCへの変異を導入する工程、及び/又は、配列番号152の65位に相当する位置にAからTへの変異を導入する工程、及び/又は、配列番号153の24位に相当する位置にAからTへの変異を導入する工程を含む、低花粉形成能ステビア植物体を作出する方法。
- 変異の導入が、突然変異誘発処理によって行われる、請求項23に記載の方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PE2021001678A PE20212081A1 (es) | 2019-04-11 | 2020-04-07 | Planta de stevia con baja formacion de polen |
EP20786908.2A EP3954203A4 (en) | 2019-04-11 | 2020-04-07 | STEVIA PLANT WITH LOWER ABILITY TO FORM POLLEN |
JP2021513651A JPWO2020209266A1 (ja) | 2019-04-11 | 2020-04-07 | |
CN202080027903.2A CN113677195A (zh) | 2019-04-11 | 2020-04-07 | 花粉形成能力低的甜菊植物 |
BR112021020049A BR112021020049A2 (pt) | 2019-04-11 | 2020-04-07 | Planta de estévia, semente, tecido, cultura de tecido ou célula, métodos para produzir uma planta de estévia, um extrato de estévia, um produto purificado de glicosídeo de esteviol, um alimento ou bebida, uma composição adoçante, um sabor ou um medicamento e para selecionar uma planta de estévia, extrato, e, kit |
AU2020270686A AU2020270686A1 (en) | 2019-04-11 | 2020-04-07 | Stevia plant having less ability to form pollens |
US17/601,596 US20220177901A1 (en) | 2019-04-11 | 2020-04-07 | Stevia plant having less ability to form pollens |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-075611 | 2019-04-11 | ||
JP2019075611 | 2019-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020209266A1 true WO2020209266A1 (ja) | 2020-10-15 |
Family
ID=72751462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/015729 WO2020209266A1 (ja) | 2019-04-11 | 2020-04-07 | 花粉形成能の低いステビア植物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220177901A1 (ja) |
EP (1) | EP3954203A4 (ja) |
JP (1) | JPWO2020209266A1 (ja) |
CN (1) | CN113677195A (ja) |
AR (1) | AR118616A1 (ja) |
AU (1) | AU2020270686A1 (ja) |
BR (1) | BR112021020049A2 (ja) |
PE (1) | PE20212081A1 (ja) |
WO (1) | WO2020209266A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022220152A1 (ja) * | 2021-04-15 | 2022-10-20 | サントリーホールディングス株式会社 | 栄養成分リッチなステビア植物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
WO2010038911A1 (en) | 2008-10-03 | 2010-04-08 | Morita Kagaku Kogyo Co., Ltd. | New steviol glycoside |
WO2016049531A1 (en) * | 2014-09-26 | 2016-03-31 | Purecircle Usa Inc. | Single nucleotide polymorphism (snp) markers for stevia |
WO2018124142A1 (ja) | 2016-12-27 | 2018-07-05 | サントリーホールディングス株式会社 | 高レバウジオシドc含有ステビア植物 |
WO2019074089A1 (ja) * | 2017-10-12 | 2019-04-18 | サントリーホールディングス株式会社 | 高レバウジオシドm含有ステビア植物 |
WO2020027155A1 (ja) * | 2018-07-31 | 2020-02-06 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6255557B1 (en) * | 1998-03-31 | 2001-07-03 | Her Majesty The Queen In Right Of Canada As Represented By The Ministerof Agriculture And Agri-Food Canada | Stevia rebaudiana with altered steviol glycoside composition |
JPWO2006093229A1 (ja) * | 2005-03-04 | 2008-08-07 | 守田化学工業株式会社 | ステビア甘味料 |
CN114794349A (zh) * | 2014-09-02 | 2022-07-29 | 谱赛科有限责任公司 | 甜菊提取物 |
-
2020
- 2020-04-07 AR ARP200100978A patent/AR118616A1/es unknown
- 2020-04-07 US US17/601,596 patent/US20220177901A1/en active Pending
- 2020-04-07 BR BR112021020049A patent/BR112021020049A2/pt unknown
- 2020-04-07 AU AU2020270686A patent/AU2020270686A1/en active Pending
- 2020-04-07 PE PE2021001678A patent/PE20212081A1/es unknown
- 2020-04-07 CN CN202080027903.2A patent/CN113677195A/zh active Pending
- 2020-04-07 JP JP2021513651A patent/JPWO2020209266A1/ja active Pending
- 2020-04-07 WO PCT/JP2020/015729 patent/WO2020209266A1/ja unknown
- 2020-04-07 EP EP20786908.2A patent/EP3954203A4/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
WO2010038911A1 (en) | 2008-10-03 | 2010-04-08 | Morita Kagaku Kogyo Co., Ltd. | New steviol glycoside |
WO2016049531A1 (en) * | 2014-09-26 | 2016-03-31 | Purecircle Usa Inc. | Single nucleotide polymorphism (snp) markers for stevia |
WO2018124142A1 (ja) | 2016-12-27 | 2018-07-05 | サントリーホールディングス株式会社 | 高レバウジオシドc含有ステビア植物 |
WO2019074089A1 (ja) * | 2017-10-12 | 2019-04-18 | サントリーホールディングス株式会社 | 高レバウジオシドm含有ステビア植物 |
WO2020027155A1 (ja) * | 2018-07-31 | 2020-02-06 | サントリーホールディングス株式会社 | 甘味成分高含有型ステビア植物及びそのスクリーニング方法 |
Non-Patent Citations (12)
Title |
---|
BUDEGUER C.J., CAMADRO E.L., ERAZZÚ L.E: "Pollen viability and meiotic irregularities in a collection of Stevia rebaudiana (BERTONI) BERTONI cultivated in TUCUMAN, ARGENTINA", JOURNAL OF BASIC AND APPLIED GENETICS, vol. XXIX, no. 2, 2018, pages 49 - 57, XP055748604, ISSN: 1852-6233 * |
LIVAK, K. J., BIOMOL. ENG., vol. 14, 1999, pages 143 - 149 |
LIVAK, K. J., GENET). ANAL., vol. 14, 1999, pages 143 |
LYAMICHEV, V. ET AL., SCIENCE, vol. 260, 1993, pages 778 - 783 |
METHOD IN MOLECULAR BIOLOGY, vol. 1391, pages 113 - 123 |
MORRIS T. ET AL., J. CLIN. MICROBIOL., vol. 34, 1996, pages 2933 |
MORRIS T. ET AL., J. CLIN.MICROBIOL., vol. 34, 1996, pages 2933 |
OHTA ET AL., J. APPL. GLYCOSCI., vol. 57, no. 3, 2010, pages 199 - 209 |
RAJI AKINTUNDE ABDULLATEEF , NOR HAFIZAH ZAKARIA , NOR HAZWANI HASALI ,MOHAMAD OSMAN: "Studies on pollen viability and germinability in accessions of Stevia rebaudiana Bertoni", INTERNATIONAL JOURNAL OF BIOLOGY, vol. 4, no. 3, 13 June 2012 (2012-06-13), pages 72 - 79, XP055748603, ISSN: 1916-9671, DOI: 10.5539/ijb.v4n3p72 * |
SAMBROOKFRITSCHMANIATIS: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP3954203A4 |
VANESSA M. DE OLIVEIRA , ELIANA R. FORNI-MARTINS , PEDRO M. MAGALHÃES , MARCOS N. ALVES: "Chromosomal and morphological studies of diploid and polyploid cytotypes of Stevia rebaudiana (Bertoni) Bertoni (Eupatorieae, Asteraceae", GENETICS AND MOLECULAR BIOLOGY, vol. 27, no. 2, 2004, BR, pages 215 - 222, XP055748601, ISSN: 1415-4757, DOI: 10.1590/S1415-47572004000200015 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022220152A1 (ja) * | 2021-04-15 | 2022-10-20 | サントリーホールディングス株式会社 | 栄養成分リッチなステビア植物 |
Also Published As
Publication number | Publication date |
---|---|
EP3954203A1 (en) | 2022-02-16 |
AU2020270686A1 (en) | 2021-11-25 |
US20220177901A1 (en) | 2022-06-09 |
EP3954203A4 (en) | 2023-01-18 |
CN113677195A (zh) | 2021-11-19 |
JPWO2020209266A1 (ja) | 2020-10-15 |
PE20212081A1 (es) | 2021-10-28 |
BR112021020049A2 (pt) | 2021-12-07 |
AR118616A1 (es) | 2021-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3695714A1 (en) | Rebaudioside m-rich stevia plant | |
US11732313B2 (en) | High-sweetening-content stevia plant and method for screening same | |
US20230225273A1 (en) | Stevia plant having high rebaudioside m content ratio and screening method for same | |
JP2024012453A (ja) | チラミン低含有ステビア植物 | |
JP7520722B2 (ja) | 高レバウジオシドd含有ステビア植物 | |
WO2020209266A1 (ja) | 花粉形成能の低いステビア植物 | |
WO2020209265A1 (ja) | 花芽形成能の低いステビア植物 | |
WO2021230256A1 (ja) | 高レバウジオシドd含有ステビア植物 | |
EP4151082A1 (en) | High steviol glycoside-containing stevia plant and method for screening same | |
WO2021230258A1 (ja) | 高レバウジオシドe含有ステビア植物体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20786908 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021513651 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021020049 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020786908 Country of ref document: EP Effective date: 20211111 |
|
ENP | Entry into the national phase |
Ref document number: 2020270686 Country of ref document: AU Date of ref document: 20200407 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112021020049 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211005 |